THE EFFECTS OF ATOMOXETINE ON COGNITIVE PERFORMACE AND NEUROPLASTICITY AFTER TRAUMATIC BRAIN INJURY by Reid, Wendy
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2008
THE EFFECTS OF ATOMOXETINE ON
COGNITIVE PERFORMACE AND
NEUROPLASTICITY AFTER TRAUMATIC
BRAIN INJURY
Wendy Reid
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Nervous System Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1562
School of Medicine  
Virginia Commonwealth University  
 
 
This is to certify that the dissertation prepared by Wendy Murdock Reid entitled THE 
EFFECTS OF ATOMOXETINE ON COGNITIVE PERFORMACE AND 
NEUROPLASTICITY AFTER TRAUMATIC BRAIN INJURY has been approved by 
his or her committee as satisfactory completion of the thesis or dissertation requirement 
for the degree of Doctor of Philosophy 
 
 
 
 
Robert J. Hamm, Ph.D.,   
 
_______________________________________________________________________ 
 
Linda Phillips, Ph.D., School of Medicine 
 
 
 
Thomas Reeves, Ph.D., School of Medicine 
 
 
 
John T. Povlishock, Ph.D., School of Medicine 
 
 
 
Aron H. Lichtman, Ph.D., School of Medicine 
 
 
 
John T. Povlishock, Ph.D., Department Chairman 
 
 
 
[Click here and type your School or College Dean's Name] 
 
 
 
Dr. F. Douglas Boudinot, Dean of the School of Graduate Studies 
 
 
[Click here and type the Month, Day and Year this page was signed.] 
 © Wendy Murdock Reid 2008 
All Rights Reserved 
 
 THE EFFECTS OF ATOMOXETINE ON COGNITIVE PERFORMACE 
AND NEUROPLASTICITY AFTER TRAUMATIC BRAIN INJURY 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
by 
 
WENDY MURDOCK REID 
Bachelor of Science, North Carolina State University, 1999 
 
 
 
Major Director:  Robert J. Hamm, Ph.D. 
Professor, Department of Psychology 
 
Co-Director: Linda Phillips, Ph.D. 
Professor, Anatomy and Neurobiology 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2008
ii 
Acknowledgements 
 
 I would like to thank my graduate mentor, Dr. Robert Hamm, for taking a chance 
me on as a PhD. Candidate, especially since I was an anatomy student with an interest in 
behavior.  I have learned so much from you over the past few years, and I appreciate your 
guidance, patience and insight.  I would also like to especially thank Dr. Linda Phillips 
for working with me and supporting my research and ideas.  Thanks to the Department of 
Anatomy and Neurobiology and Dr. John Povlishock for supporting and training me. 
Also, I would like to thank my other distinguished committee members Thomas Reeves, 
and Aron Lichtman. It has been a great pleasure to know and work with all of them, and I 
have learned much from watching and interacting with them.        
 
I would like to thank my fellow graduate students and friends, Janna Harris, Niki 
Kokiko, Mark Whiting, Katharine Eakin and Kelly Warren, who have leant me their 
support and advice throughout this endeavor. I have enjoyed our camaraderie and look 
forward to future collaborations.  In addition, I would like to thank three technicians who 
have been a tremendous help in the experiments presented, as well as am excellent source 
of technical knowledge: Nancy Nixon-Lee, Raiford Black, and Lesley Harris.  Finally, I 
am very grateful to my husband, Timothy Reid, for his constant encouragement and 
support both intellectually and personally, and for his patience with me during 
comprehensives and the writing of this dissertation.  Thanks to my parents for 
encouraging my curiosities over the years and for giving me strong ethical principles and 
a desire to contribute to society.  I hope that I will always make my family proud.  
Finally, I would like to thank my dog, Mr. Magoo, who never asked “When are you 
going to be done with your dissertation?” and Steven Pinker for writing a book that first 
ignited my fascination with cognitive neuroscience.  
 
Partial funding for this dissertation was supported by Eli Lilly and Company.   
 
 
 
 
 
 
iii 
Table of Contents 
Page 
Acknowledgements ............................................................................................................. ii 
List of Figures .................................................................................................................. viii 
List of Abbreviations……………………………………………………………………..ix 
Abstract…………………………………………………………………………………...xi 
INTRODUCTION………………………………………………………………………...1 
 
 Epidemiology of TBI……………………………………………………………...1 
 
 Functional Deficits……………………………………………………………...…5 
 
 Cognitive Deficits…………………………………………………………………7 
   
  Attention and TBI………………………………………………..………..8 
   
  Executive Function and the Frontal Lobe Syndromes………………...…..9 
   
  Memory and the Temporal Lobe Syndromes…………………………....10 
    
 The Hippocampus and Learning and Memory…………………………..………11 
 
  The anatomy and role of distinct hippocampal subregions………...……13 
   
  The hippocampus and TBI……………………………………………….15 
 
 Neuropathology and Mechanisms of Brain Injury…………………….…………16 
   
  Classification of Brain Injury: Primary, Secondary, Focal and Diffuse....16 
   
  Metabolic and Neurochemical Changes…………………………………19 
 
  Other Mechanisms Involved in TBI……………………………………..22 
 
  Mechanisms Involved in Neural Recovery………………………………24 
iv 
   
  Pharmacological Approaches to Treatment of TBI……………………...28 
  
 The Catecholamines: Norepinephrine and Dopamine…………………………..33 
 
  Norepinephrine…………………………………………………………..33 
    
Norepinephrine receptors and the Norepinephrine Transporter…33 
 
Norepinephrine and Cognition…………………………………..35 
 
Norepinephrine and Mechanisms Important to TBI……………..39 
 
  Dopamine……………………………………………………………..….41 
   
   Dopamine Receptors………………………………………….….41 
 
   Dopamine and Cognition………………………………………...43 
 
  The Catecholamines and TBI…………………………………………….44 
 
  Catecholamine theory of recovery……………………………………….47 
 
 Atomoxetine……………………………………………………………………..53 
 
 Outcome Markers………………………………………………………………..56 
 
  Growth associated protein-43……………………………………………56 
 
  Synaptophysin…………………………………………………...……….61 
 
  Brain-derived Neurotrophic Factor (BDNF)…………………………….63 
 
 Summary…………………………………………………………………………66 
 
 
 METHODS 
 
 Subjects…………………………………………………………………………68 
 
v 
 Drug Preparation…………………………………………………………………68 
 
 Experimental models of TBI: Rationale for L-FPI………………………………67 
 
 Surgical Preparation……………………………………………………………...70 
 
 Fluid-Percussion Brain Injury…………………………………………….….......70 
 
 Behavioral Outcome Assessment: Morris Water Maze………………………….76 
 
EXPERIMENTAL RATIONALE, DESIGN, AND RESULTS 
 
 Experiment 1: Optimum Dose Determination…………………………………...80 
 
  Rationale………………………………………………………………....80 
 
  Design…………………………………………………………………....81 
 
  Results……………………………………………….…………………...81 
 
  Discussion………………………………………………………………..82 
 
 Experiment 2: Examination of Therapeutic Window……………………………90 
 
  Rationale…………………………………………………………………90 
 
  Design……………………………………………………………………91 
 
  Results……………………………………………………………………91 
 
  Discussion………………………………………………………………..91 
 
Experiment 3: Termination of Chronic Administration Before MWM Testing…97 
 
  Rationale……………………………………………………………....…97 
 
  Design……………………………………………………………………97 
 
  Results……………………………………………………………………97 
 
vi 
  Discussion…………………………………………………………….….98 
 
Experiment 4: Administration of a Single Dose of Atomoxetine…………..…..103 
 
  Rationale……………………………………………………………..…103 
 
  Design……………………………………………………………..……104 
 
  Results………………………………………………………………..…105 
 
  Discussion……………………………………………………………....105 
 
Experiment 5: Effects of Atomoxetine on Protein Expression of Plasticity     
               Markers……………………………………………… ...108 
 
  Rationale………………………………………………………………..108 
 
  Design…………………………………………………………………..109 
 
   Tissue Preparation and Western Blot Analysis…………………109  
 
  Results………………………………………………………………..…111 
 
  Discussion………………………………………………………………113 
 
 Experiment 6:  Immunohistochemistry of GAP-43 in the Hippocampus………129 
 
  Rationale………………………………………………………………..129 
 
  Design…………………………………………………………………..129 
    
   Immunohistochemistry Procedure……………………………...129 
 
   Densitometric Analysis………………………………………....130 
 
  Results.………………………………………………………………….130 
 
  Discussion……………………………………………………………....132 
 
 
vii 
CHAPTER 4 
 
GENERAL DISCUSSION……………………………………………………………..140 
 
           Summary of Results………………………………………………………….....140 
 
           Clinical Implications…………………………………………………………….141 
 
           Potential Mechanism for Atomoxetine’s Effects……………………………..…144 
 
           Conclusions……………………………………………………………………...151 
 
List of References ............................................................................................................155 
Vita……………………………………………………………………………………...195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
List of Figures 
Page 
Figure 1: A diagram of the hypothesized biphasic model .................................................33 
Figure 2: A picture of the fluid percussion injury device (FPI) .........................................74 
Figure 3: Histology following Lateral-Fluid Percussion Injury ........................................76 
Figure 4: A cartoon of the Morris Water Maze .................................................................80 
Figure 5: MWM results for Experiment 1. ........................................................................86 
Figure 6: MWM results for Sham Groups. ........................................................................88 
Figure 7: Swim Speeds for Experiment 1 ..........................................................................90 
Figure 8: MWM Results Following Delayed Atomoxetine Treatment .............................97 
Figure 9: Results of Terminating Chronic Atomoxetine Treatment before MWM .........103 
Figure 10: MWM Results Following Administration of a Single Dose of Atomoxetine..108 
Figure 11: Ipsilateral GAP-43 Western Blot ...................................................................122 
Figure 12: Contralateral GAP-43 Western Blot...............................................................124 
Figure 13: Ipsilateral Synaptophysin Western Blot .........................................................126 
Figure 14: The expression of BDNF in the Ipsilateral and Contralateral Hippocampus. 128 
Figure 15: Immunohistochemistry for GAP-43 in the Ipsilateral Hippocampus .............137 
Figure 16: GAP-43 Densitometric analysis in the Contralateral Hippocampus ..............139 
Figure 17: Pharmacological Treatments Following TBI .................................................153 
ix 
List of Abbreviations 
 
 
ABC  Avidin-biotin-peroxidase complex 
 
Ach  Acetylcholine 
 
AD  Alzheimer’s disease 
 
ADHD  Attention Deficit Hyperactivity Disorder 
 
atm  Atmosphere 
 
BDNF  Brain-derived Neurotrophic factor 
 
CCI  Controlled cortical impact 
 
CNS  Central nervous system 
 
DA  Dopamine 
 
FPI  Fluid percussion injury 
 
ICP  Intracranial pressure 
 
GABA  Gamma aminobutyric acid 
 
GAP-43 Growth-Associated Protein- 43 
 
h  hour(s) 
 
IML  Inner molecular layer 
 
i.p.  intraperitoneal 
 
IR  Immunoreactivity 
 
LTP  Long-term potentiation 
 
MAG  Myelin Associated Glycoproteins 
x 
 
mRNA  Messenger ribonucleic acid 
 
MWM  Morris Water Maze 
 
NE  Norepinephrine 
 
NET  Norepinephrine Transporter 
 
NGF  Nerve growth factor 
 
NT  Neurotransmitter 
 
PID  Post-injury day 
 
RFD  Remote functional Depression 
 
SEM  Standard error of the mean 
 
SLM  Stratum lacunosum moleculare 
 
SO  Stratum oriens 
 
SR  Stratum radiatum 
 
TBI  Traumatic brain injury 
 
VTA  Ventral Tegmental Area 
 
 
 xi 
Abstract 
 
 
 
THE EFFECTS OF ATOMOXETINE ON COGNITIVE PERFORMACE 
AND NEUROPLASTICITY AFTER TRAUMATIC BRAIN INJURY 
 
By Wendy Murdock Reid 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2008 
 
Major Director: Robert J Hamm, PhD., Department of Psychology 
Co-Director: Linda Phillips, Ph.D., Department of Anatomy and Neurobiology  
 
 
 
 
Catecholaminergic neurotransmission is regionally altered following injury, and 
drugs aimed at these systems offer promising avenues for post-TBI pharmacotherapies. 
Atomoxetine is a selective norepinephrine transporter (NET) inhibitor currently indicated 
for treatment of attention-deficit hyperactivity disorder (ADHD).  The studies in this 
dissertation were designed to test the efficacy of atomoxetine for treating cognitive deficits 
following experimental TBI and the potential mechanism for any beneficial effect.  The 
first part of the study focused on behavioral recovery following atomoxetine treatment.  
xii 
Several important questions of dose, therapeutic window, and duration of treatment were 
addressed in these studies.  Sprague-Dawley rats were subjected to lateral fluid-percussion 
injury (L-FPI) of moderate severity (2.08 atm +/- .05). Four experiments were performed.  
In the first study, atomoxetine (.3 mg/kg, 1mg/kg, 3 mg/kg, or 9 mg/kg) or vehicle was 
administered daily on post injury days (PID) 1-15.  Cognitive assessment was performed 
using the Morris water maze on PID 11-15.   L-FPI resulted in significant cognitive 
impairment when compared to Sham-Injury. Treatment with lower doses of atomoxetine 
(.3mg/kg, 1mg/kg, and 3mg/kg) significantly attenuated the cognitive deficits in injured 
animals. Treatment with the higher dosage (9mg/kg) of atomoxetine resulted in animals 
that were not significantly different than injured-vehicle treated animals. The optimal 
response was achieved using 1 mg/kg atomoxetine.  In the second study, treatment with 
atomoxetine (1mg/kg) or vehicle was delayed for 11 days post-injury. Rats were 
administered atomoxetine daily for 15 days and cognitive assessment was performed on 
PID 25-29.  In this study, treatment with atomoxetine (1 mg/kg) did not result in improved 
cognitive performance.  In the next study atomoxetine was given daily on PID 1-7 and then 
treatment was terminated.  The animals were tested in the MWM on PID 11-15.  We found 
that atomoxetine treatment for 7 days post-injury provides an enhancement of cognitive 
deficits that is not significantly different from sham animals.   We then investigated 
whether a single treatment of atomoxetine 24 h after brain injury could influence 
behavioral outcome on days 11-15. From this study, we found a single dose of atomoxetine 
is not as effective as chronic treatment.  Finally, we investigated changes in the protein 
expression of brain-derived neurotrophic factor, growth-associated protein-43, and 
xiii 
synaptophysin on day 7 PID to investigate what effect atomoxetine may have on brain 
plasticity and regeneration. We found that atomoxetine can enhance both GAP-43 and 
BDNF, but not synaptophysin at this time point.  In conclusion, this is the first study to 
show that low doses of atomoxetine initiated early after experimental traumatic brain 
injury results in improved cognition.  Furthermore, we show that enhancement of 
catecholamines via atomoxetine treatment during periods of postinjury-induced plasticity 
can provide long-term functional and structural benefits.    
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CHAPTER 1 INTRODUCTION 
 
Epidemiology of TBI 
 Traumatic brain injury is one of the leading causes of death and disability, and a 
serious health concern in the United States (NIH conference 1999, Rutland-Brown et al., 
2006).  In 2002 alone, TBI accounted for approximately 6.5% of all deaths occurring in the 
United States (CDC, 2002).  Globally, TBI is the leading cause of death of people under 45 
and accounts for 1% of all deaths.  It is reported that by 2020 TBI will be the 3rd leading 
cause of death and disability in the world (Murray and Lopez, 1997).  In the Unites States, 
the NHIS and CDC report that approximately 1.4-1.5 million brain injuries occur annually 
(Langois et al., 2003, 2006).  Of these, approximately 1.1 million people will receive care 
from an emergency room, 235,000 people will require hospitalization and 50,000 will die.  
Acute management of TBI and various prevention measures have led to fewer fatalities 
and an overall increase in the number of survivors.  The increased survival rates have led 
to increased numbers of patients facing the long term consequences of TBI.  The National 
Hospital Discharge Survey estimates 70,000 to 90,000 people will endure long-term loss of 
function and disability, including physical, neuropsychological, emotional, and behavioral 
impairments.  This has led to an estimated 5.3 million Americans, or 2% of the nation’s 
population, living with TBI related disabilities (Thurman et al, 1999; Langlois et al., 2006).  
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 The leading causes of traumatic brain injury include falls, motor vehicle or traffic 
related crashes, and assault (Langlois et al., 2006).  TBI occurs most often in young adults, 
with a peak incidence at age 15-19.  Smaller peaks occur in younger children age 0-4 and 
in the elderly, 75 and up.  Males show twice the incidence rate and a death rate 3.3 times 
higher than females (Thurman et al., 1999).  In the U.S higher TBI rates are seen in 
minorities and lower socioeconomic groups, likely because of exposure to firearms and 
higher homicide rates. 
 TBI can affect all major areas of functioning, which makes the economic 
consequences of TBI astonishing.  TBI-related disabilities have been linked to poor 
outcome in vocational functioning and often prevent the successful reentrance of patients 
into society (Cicerone et al., 2004).  Direct and indirect TBI-related costs are estimated at 
nearly 60 billion dollars a year (Finkelstein et al., 2006).  The individual health care costs 
for the patient and the patient’s family are also enormous.  Hospitalization charges alone 
can range from $32,000 to $100,000 (Davis et al., 2007).  The lifetime costs for one person 
surviving a severe TBI can be as high as $4 million (National Institute of Neurological 
Disorders and Stroke 1989).  This takes into account costs associated with post-injury 
rehabilitation and treatment, unemployment, and family care.  The high costs associated 
with TBI often leave individuals and families at an increased risk for filing for bankruptcy 
(Hollingworth et al., 2007).  The statistics clearly highlight the need for research that can 
elucidate the underlying pathology of TBI and find effective treatments for these patients. 
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Clinicians most often distinguish brain injury as mild, moderate, or severe.  
Although studies vary, approximately 80% of brain injuries are classified as mild, 10% as 
moderate, and 10% as severe (Bruns and Hauser, 2003).  The Glasgow Coma Scale (GCS) 
is the most widely used method to classify the severity of injury and is based upon patient 
assessment of eye opening, verbal ability, and motor ability.  Other factors such as duration 
of unconsciousness, skull fractures, ischemia, seizures, and computerized tomography 
(CT) scan reports are taken into account when determining GCS score.  A patient who is 
able to follow commands, is fully oriented, and has spontaneous eye opening would 
receive a GCS score of 15.  A patient with no verbal or motor response and no eye opening 
would receive a GCS score of 3.  Mild injuries then correspond to a score of 13-15, 
moderate injuries to a score of 9-12, and severe injuries to a score of 3-8.  The scores have 
prognostic value regarding eventual neurological recovery and rehabilitation, however, 
because the score is left open to doctor’s interpretation the objectivity of the GCS often 
comes into question.  Still mild, moderate, and severe injuries are characterized by very 
different pathologies and result in varying degrees of motor and cognitive deficits. 
A TBI may be classified as mild if loss of consciousness or the period of 
disorientation and confusion is less than 30 minutes.  Mild injuries are the most prevalent 
type of TBI, but they are often missed at the initial time of injury or not reported because 
patients may not present any clear signs or symptoms.  Cognitive sequelae that usually 
develop within the first month following mild injuries include problems with attention, 
information processing and memory.  Although studies vary considerably, most suggest 
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there is a progressive diminution of cognitive deficits over the first year post-injury (Katz, 
and DeLuca, 1992).  
Moderate brain injury is defined as an injury resulting in loss of consciousness of 
30 minutes to 6 h and a GCS of 9-12.  There is great variation in the outcome of moderate 
severity and it very difficult to study because of variations in the definition of what 
constitutes a moderate injury.  There is a low mortality rate of approximately 7-9%.   The 
degree of deficits as well as the recovery period from moderate injury is significantly 
longer than what is seen with mild injury.  Moderate injury results in increased 
unemployment and increased cognitive deficits compared to mild injury (Rimel et al., 
1982).  Although memory problems are the most common complaint, patients also suffer 
from problems with attention, concentration, information processing, “executive 
functions”, impulsiveness, perseveration, and language complications.  Studies show that 
at one year post-injury, patients still have memory impairments and behavioral problems 
that prevent full recovery (Tabaddor et al., 1984).  
Severe TBI is defined by an injury that results in a loss of consciousness of more 
than 6 h and a GCS of 3-8.  The incidence of mortality and disability are highest in this 
group.  The lifelong costs for one person surviving a severe TBI can be as high as 4 
million, and few people are able to return to work (National Institute of Neurological 
Disorders and Stroke 1989; Wehman et al., 1993).  Significant deficits in memory, 
attention, and information processing, as well as a number of motor, behavioral, and 
emotional problems often compromise a patient’s independence and quality of life and 
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require them to have assisted living situations (Colantonio et al., 2007).  Survivors of 
severe TBI have the highest risk for suffering persistent, life-long deficits following injury. 
Functional Deficits 
 TBI results in a myriad of functional impairments including physical, neurological, 
psychological, and cognitive deficits.  Although, treatment strategies have focused on 
treating the symptoms of these disorders individually, it is very common for patients to 
experience them simultaneously.  The extent and type of deficits reflects a number of 
factors including the severity of diffuse axonal injury and the location, depth, and volume 
of focal injury (Katz and Alenander, 1994).  Although focal lesions may produce 
neurobehavioral syndromes depending on the location of damage, it is generally believed 
that diffuse injury leads to a more global dysfunction of circuits.  Other factors such as age, 
gender, preexisting morbidities, injury severity and extracranial or systemic injury can also 
affect outcome.  Therefore, the recovery times are variable, and may never be reached for 
some patients. 
 From a clinical perspective, the etiology can be very difficult to classify 
which results in variable clinical management (Ghajar et al., 1995).  A comprehensive 
integrated neurological assessment which takes into account biological disturbances in 
brain function, a patient’s emotional and psychological reactions to impairments in 
cognition and behavior, including awareness and acceptance of these impairments, and 
finally disruptions of relationships and work capacities is needed to develop an effective 
treatment approach that focuses on the patient’s problems.  However, many patients have 
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multiple injuries and life-threatening situations which prevent immediate neurological 
assessment and treatment.  In addition, it can be difficult to interpret which aspects of 
cognition are impaired using standard behavioral paradigms.  Various imaging tools have 
allowed for more accurate clinical assessment of TBI.  Structural imaging using computed 
tomography (CT) and magnetic resonance (MR) allows for early detection of abnormalities 
such as hemorrhage, contusion, edema, midline shift, and herniation that may require 
surgery and special treatment (Furlow, 2006).  In addition, the neuropsychological 
sequelae of TBI can be evaluated using functional imaging techniques such as single-
photon emission CT (SPECT), positron emission tomography (PET) and functional-MRI 
(fMRI), which captures brain activity or “function” as reflected through cerebral metabolic 
rate (CMR) or cerebral blood flow (CBF).  These tools have allowed more accurate 
diagnoses and better treatment protocols.    
   The initial and transient sequelae of TBI, during the period of posttraumatic 
amnesia, can include periods of delirium, agitation, confusion, disorientation, and amnesia.  
Patients often initially present posttraumatic headaches, vertigo, anxiety, autonomic 
dysfunction, as well as sensory and motor deficits.  Delayed and persistent movement 
impairments, epilepsy, chronic pain, sleep disruption/chronic fatigue and/or some sensory 
impairment commonly develop following injury.  There is also a significant amount of 
evidence to suggest TBI leads to a number of affective psychiatric disorders including, 
aggressive, and anxiety disorders and depression (for a review, see Fleminger, 2008).  
These often lead to mood disorders and dramatic personality changes (NIH Consensus 
Conference, 1999), which may be a direct result of TBI related damage or indirectly 
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caused by the social consequences of TBI.  TBI patients are at a very high risk of divorce, 
suicide, unemployment, and substance abuse, which further exaggerates the already 
stressful situation (NIH Consensus Conference, 1999; Bushnik et al., 2003).    
  
Cognitive Deficits 
  Initial and persistent cognitive deficits are often the most prominent features 
following TBI of any severity (for a review, see McAllister, 2008).  Although, the 
cognitive deficits observed vary from individual to individual and severity of injury, there 
is a degree of consistency as to the nature and frequency of deficits observed.  The most 
common complaints include attentional impairments, frontal executive impairments (e.g. 
problem solving, mental flexibility, initiation and inhibition), language impairments, and 
memory and learning dysfunction.  The neurobiology and neurochemistry of attention, 
executive function, and memory and the TBI-induced changes in these processes will be 
discussed in more detail below. Important to this discussion is the evidence that suggests 
the neural circuitry and neurochemistry of different components of attention and memory 
overlap significantly.  For example, the hippocampus, long recognized as a crucial 
structure in declarative memory processes, has recently been shown to have extensive 
connections to areas of the prefrontal cortex that are involved in working memory and 
appears to play a role in aspects of attention (Wall et al., 2001).  Likewise strategic 
encoding and retrieval processes, thought to be centered in temporal lobe structures and the 
hippocampus, also engage areas of the frontal cortex (Kapur et al., 1995; Nyberg et al., 
1996).  Therefore, it must be remembered that these cognitive processes are served by a 
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distributed network of interacting brain regions, rather than being localized to a single 
region.       
Attention and TBI  
Impairments in attention appear to be a universal effect of TBI at all levels of injury 
severity (Gronwall, 1987; van Zomeren and Brouwer, 1994; Raskin et al., 2000).  
Attention is not a unitary concept and is broadly divided into subcomponents that include 
general arousal, selective, sustained and divided attention, as well as information 
processing and executive aspects (van Zomeren and Brouwer, 1994).  These components 
of cognition involve a network of brain regions including the parietal cortex, dorsal frontal 
cortex, and cingulated regions, working with the basal ganglia, thalamus, and 
hippocampus.  The brain stem is responsible for the overall attentional “tone” or degree of 
arousal (Mesulam, 2000).  Because attention is important at many levels of cognition, 
these elements reflect widely dispersed neural networks that can be disrupted by both focal 
and diffuse injury during TBI.  One of the most frequent complaints following injury is 
reduced information processing speed or a reduction in cognitive efficiency, which is 
thought to result from diffuse white matter dysfunction.  TBI patients consistently 
demonstrate reduced reaction time (RT) proportional to task severity (Gronwall, 1987).  
Although improvements are seen over time, persistent deficits in these tasks are common 
(Lezak, 1995).  
 In addition to slowed information processing, other aspects of attention are also 
affected, especially in moderate to severe TBI patients (Schmitter-Edgecombe and Kibby, 
1998).  Disorders in selective attention (the ability to inhibit irrelevant processes or 
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distractions), sustained attention (the ability to sustain attention over a period of time, or 
vigilance), and divided attention (the ability to divide attention between two or more 
sources, multi-tasking) are all frequent complaints following brain injury (Park et al., 1999; 
Whyte et al., 2000; Brouwer et al., 2001).  In addition, patients often perform worse in 
tasks that require components of working memory and executive functions, thus once 
again it is important to remember that a number of the domains of attention are dependent 
on other cognitive domains, as well as emotional functioning (Rios et al., 2004).  The 
evidence taken together suggests attentional deficits are common following both mild TBI, 
in which the deficits may resolve in 1-3 months (Gronwall, 1991),  as well as following 
more moderate to severe injuries, in which persistent long-term deficits are more common 
(Levine et al., 2000). 
Executive Functions & Frontal Lobe Syndrome 
 Executive function is a broad term that encompasses many aspects of higher-order 
behavioral processes such as reasoning, planning, inhibiting inappropriate behaviors, 
organizing, and sequencing, as well as the executive memory processes and executive 
attentional processes (Eslinger et al., 1996).  Studies in patients with moderate to severe 
TBI reveal deficits in conceptual reasoning and flexibility (Millis et al., 2001), strategic 
memory (Levin and Goldstein, 1986), planning (Leon-Carrion et al., 1998) and attentional 
executive processes (Levin et al., 1991).  These processes are considered to be the domain 
of the frontal lobes and its complex projections and feedback loops, and thus often referred 
to as frontal lobe syndromes.   Many of these cognitive processes are commonly affected 
by focal and diffuse damage to cortical tissue (Crepeau and Scherzer 1993; Levin et al., 
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1992; Leon-Carrion et al., 1998).   The anterior regions of the brain are particularly 
vulnerable to contusional damage (Levin et al., 1992), but also may experience some 
degree of diffuse axonal injury (Gentry et al., 1988).          
An understanding of frontal lobe functions has been advanced by an understanding 
of the frontally guided networks involving the prefrontal cortex, posterior cortex, basal 
ganglia, ventral striatum, and thalamus (Schultz, 2001).  Neuroimaging studies in humans 
and non-human primates have found the dorsolateral and ventrolateral prefrontal cortex 
and parietal cortex are particularly important areas for supporting working memory and the 
components of executive functioning (e.g., switching between tasks and inhibition).  
Anticipation and reward behavior, which are important for many aspects of executive 
function including the motivational aspects, involve the cortex, thalamus, and ventral 
striatum, with complex cortico-striatal-thalamo-cortical loops.  Therefore focal or diffuse 
damage to any of these brain regions can have dramatic effects on executive function, as 
well as memory and attention.  
Memory & The temporal lobe syndromes 
 Memory impairments are among the most common cognitive complaints and a 
cardinal feature of TBI.  In the acute stages following injury intervals of retrograde 
amnesia and posttraumatic amnesia are dramatic.  As time progresses, many aspects of 
memory impairment become evident and often persist though life (King et al., 1995). 
Memory is often subdivided into: 1.) declarative memory (explicit), which includes both 
episodic memory for events, and semantic memory for general facts and 2.) implicit 
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memory, which includes procedural learning, priming, and conditioning (Markowitsch, 
2000).  
 Disruption to episodic memory processes is a hallmark feature of TBI, whereas 
implicit, or procedural memory (e.g. motor skills or puzzle solving), is generally left 
unimpaired (Shum et al., 1996; Richardson, 2000).  Explicit memory is under the domain 
of the medial temporal lobes, thalami, and other structures and is the result of at least three 
different types of processing referred to as: encoding, consolidation, and retrieval.  
Encoding refers to the process by which information is acquired and processed when first 
encountered.  This includes associating new information with previous knowledge so that 
one can integrate knowledge with what one already knows.  Consolidation refers to the 
processes by which new information is converted to long-term storage, and is accompanied 
by changes in gene and protein expression and subsequent structural changes.  Retrieval 
refers to the processes that recall the stored information and bring information from many 
locations together.  Some studies have found dysfunction at all stages of memory 
processing (Curtiss et al., 2001), however , recent clinical studies suggest TBI patients 
suffer from deficits in consolidation, retention, and retrieval processes rather than problems 
with encoding (Vanderploeg and Crowell, 2001, Curtiss and Vanderploeg, 2001).    
 
The Hippocampus and Learning & Memory  
 The hippocampus is one of the most intensively researched structures in the central 
nervous system.  The hippocampus is an important region involved in acquisition, 
consolidation of explicit memories, which can be easily investigated in animals using 
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paradigms that look at spatial learning, or contextual learning (Anagnostaras et al., 2001; 
Morris et al., 2003).  The hippocampus is also involved in retrieval of memories, although 
evidence suggests memories become independent of the hippocampus over time (Squire et 
al., 1995).   
   The rodent hippocampus extends caudally between the neocortex and 
diencephalon before curving ventrally toward the temporal lobe.  It receives polymodal 
sensory information via the entorhinal cortex and has extensive connections with 
subcortical and frontal cortical structures (Witter et al., 2004).  The hippocampal formation 
is divided into subfields based on morphological and cytoarchitectonic criteria, and 
includes the entrohinal cortex, dentate gyrus, the hippocampus proper (CA1, CA2, and 
CA3) and the subiculum.  Early studies supported the idea of hippocampal place cells 
(O’Keefe and Nadel, 1978), or an allocentric map of space that is based on relationships of 
external spatial cues with no internal reference frame.  Numerous studies have confirmed 
the hippocampus plays an integral role in spatial memory navigation and other aspects of 
memory (Morris et al., 1982; Sutherland et al., 1983; McGregor et al., 2004), but the 
specific nature still remains elusive.  In addition, considerable evidence suggests functional 
heterogeneity along the axis of the hippocampus.  The more dorsal (septal) regions of the 
hippocampus, which receive most of the structures visuospatial input, appear to be more 
important for spatial memory, and the ventral (temporal) portions are more important for 
non-spatial memory or innate information processing, such as fear-related behavior and 
anxiety.  The hippocampus is noted for the prevalence of a type of synaptic plasticity 
known as long-term potentiation (LTP, Bliss and Collingridge, 1993).  LTP that is 
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dependent on NMDA receptors has been strongly linked to memory (Martin et al., 2000), 
and to the memory-associated firing properties of hippocampal neurons (Shapiro and 
Eichenbaum, 1999). 
The anatomy and role of distinct hippocampal subregions 
The Dentate Gyrus: The dentate gyrus is composed of three distinct layers: a 
molecular layer, a granule layer, and a polymorphic layer, or hilus.  The principle cell is 
the granule cell, which consists of an elliptical cell body located within the granule cell 
layer, apical dendrites of which extend into the molecular layer, and axons collateralizing 
in the polymorphic area and extending into CA3.  The molecular layer contains very few 
cell bodies, except for some basket cells and interneurons.  The granule cells receive direct 
input from the entorhinal cortex via the perforant path and then give rise to mossy fiber 
axons that project through the hilus to area CA3. 
 The dentate gyrus is unique within the brain in being one of only two areas of the 
adult brain that has continued neurogenesis (Gross, 2000).  New granule cell neurons are 
generated from progenitor cells that reside in the subgranular zone, which borders the hilus 
and the granule cell layer within the DG (Martin and Clark, 2007).  Within one week they 
migrate a short distance to the granule cell layer and begin expressing neuronal markers.  
This formation of new granule cells as been implicated in the creation of distinct memory 
traces for very similar items or events occurring at different times, a process often referred 
to as pattern separation (Becker, 2005).    
Hippocampus Proper (CA1 and CA3): The hippocampus proper consists of CA1, 
CA2, and CA3 subregions.  The CA2 region is less characterized than CA3 and CA1, 
14 
however, the border between CA2 and CA3 is marked by the termination of the stratum 
lucidum.  The major cell type is the pyramidal cell, which forms the pyramidal cell layer, 
as well as interneurons.  The cell bodies are located within the pyramidal cell layer, and 
basal dendrites extend into the stratum oriens (SO) layer.  Apical dendrites extend through 
the stratum radiatum (SR) and stratum lacunosum-moleculare (SLM) layers.  The SR 
contains Schaffer collaterals, and the SLM contains perforant pathway fibers.  Schaffer 
collaterals extend from CA3 to CA1, mostly to the SR and to a lesser extent SO.     
CA3 connections within this region as well as to CA1 are extensive and divergent. 
On average, one granule cell neuron innervates 12 CA3 neurons; in turn, each CA3 neuron 
innervates 50 other CA3 neurons via axon collaterals, as well as 25 inhibitory cells via 
other axon collaterals (Martin and Clark, 2007).  The net result is a 600- fold amplification 
of excitation, and approximately 300-fold amplification of inhibition.   Finally, a single 
CA1 neuron may be innervated by as many as 6000 CA3 neurons.  CA1 also receives input 
from the EC perforant path fibers, of which terminate in the SLM.  Although theoretical, 
the extensive recurrent connectivity of CA3 appears suited for pattern completion, or the 
reconstruction of an output pattern from a degraded input, and it has been suggested that 
CA1 acts as a ‘novelty detector’, integrating and detecting cortical information concerning 
attention and the current situation, with stored information from the hippocampus (Lisman 
et al., 2000; 2005; Grunwald 2006).  This is supported by evidence that specific synapses 
within CA3 and CA1 undergo specific structural changes, which may underlie the 
mechanisms of LTP and LTD (Lauri et al., 2007; Massey and Bashir, 2007).  However, it 
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is far from certain what role each region of the hippocampus plays in the process of 
encoding, consolidation, and retrieval of memories.    
 The Hippocampus and TBI 
 Bilateral temporal lobe lesions around the anterior region of the hippocampus are 
invariably associated with severe memory impairments, and the hippocampus is known to 
be a vulnerable region to ischemia, seizures and TBI (Schmidt-Kastner, 1996; Lyeth et al., 
1990).  Therefore the hippocampus has been the focus of many animal studies 
investigating the effects of TBI.  Among diffuse injuries, the hippocampus is known to be 
particularly susceptible in humans, with neuronal loss occurring in greater than 80% of 
fatal TBIs (Kptapka et al., 1994).  Several studies have demonstrated a loss of cells in the 
hilus, CA3 and CA1 regions of the rodent hippocampus at various time points following 
experimental TBI (Baldwin et al., 1997, Grady et al., 2003).  Axonal injury is also 
common throughout the hippocampus following injury (Povlishock et al., 1996).  Studies 
have demonstrated alterations in granule cell mossy fiber projections (Santhakumar et al., 
2001) and subsequent synaptogenesis in CA1 following TBI (Scheff et al., 2005).  
However, cognitive deficits can exist in the absence of any overt hippocampal cell death or 
axonal injury, and therefore may reflect subtle neurochemical changes that disrupt circuitry 
(Lyeth et al., 1990).  Furthermore, long- term potentiation (LTP), a major synaptic event 
implicated in learning and memory, undergoes significant changes following experimental 
brain injury (Reeves et al., 1995).  Reports have noted significant changes in LTP as long 
as 15 days after injury (Reeves et al., 1995; Sanders, 2000).  The Morris water maze 
(MWM), radial arm maze, and other similar memory tasks that require spatial 
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discrimination are sensitive to damage in the hippocampus (Morris et al., 1982).  
Hippocampal lesions as well as experimental brain injury models have consistently 
demonstrated deficits in performance of the spatial navigation tasks of the MWM 
(Eichenbaum et al., 1990; Hamm et al., 1993).  Because TBI consistently produces 
hippocampal-dependent cognitive damage, as well as reproducible histopathology, the 
hippocampus is a unique model system for studying the neuropathology and biology of 
TBI and the effects of therapeutic treatments. 
  
Neuropathology & Mechanisms of Brain injury 
Classification of Brain Injury: Primary, Secondary, Focal, and Diffuse 
Classification of brain damage after trauma should take into account the full 
spectrum of clinical presentation and outcome.  Early classifications of brain injury helped 
identify potentially preventable complications in patients, in which TBI was considered to 
be either primary (induced by mechanical forces), which occurs at the moment of injury, or 
secondary (non-mechanical forces), which are delayed events that occur independently or 
as a direct result of primary injury.  Primary injury that occurs as a result of the initial 
insult is difficult to treat therapeutically; therefore, treatment interventions have focused on 
attenuating extensive secondary injury that does not manifest clinically until a delayed 
period of time (Werner and Engelhead, 2007).  Another classification has been derived 
based on structural brain damage after trauma using the terms focal and diffuse injury.   
Primary injury includes physical damage from contact as well as angular movement that 
can be both focal and diffuse.  Secondary injury can also be classified as focal and diffuse, 
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but is more variable than primary injury and generally involves cascades of events 
resulting from combined structural, biochemical and molecular changes.   
Focal injury typically includes lesions of the scalp, the dura and skull fractures, as 
well as contusions, intracranial hematomas, edema, alterations in cerebral blood flow, 
increased intracranial pressure, cerebral ischemia, regional hypometabolism and vascular 
changes.  One explanation for the hemorrhaging and the formation of hematomas 
following injury is the rupturing of cerebral arterioles caused by the shearing and tensile 
forces generated by the injury (Povlishock and Christman, 1995).  In most cases 
contusions, which are the hallmark of head injury, are the byproduct of hemorrhagic 
lesions within the gray matter or at the gray-white interface and contribute to neuronal 
damage and ischemia (for review, Povlishock and Katz, 2005).  Contusions are generally 
located on the frontal and temporal poles, the lateral and inferior surfaces of the frontal and 
temporal lobes, and above the Sylvian fissure (Povlishock and Christman, 1995; Gennarelli 
and Grahan, 1998; Gaetz, 2004).  Diffuse brain injury refers to a number of pathologies 
that are widely distributed including the consequences of  acceleration and deceleration 
forces on white matter, often referred to as diffuse axonal injury (DAI), diffuse vascular 
injury, diffuse hypoxic-ischemic injury, and diffuse hypometabolism.  Although the terms 
focal and diffuse refer to specific pathologies following injury, the majority of evidence 
suggests they do coexist and have common secondary and metabolic consequences. 
Therefore, experimental injury models that combine both focal and diffuse injury may 
better replicate the pathology of human head injury.   
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Understanding the pathophysiology following injury is important for understanding 
the functional deficits observed following injury and for determining an optimal treatment 
strategy.  One of the devastating consequences of injury is the loss of neural, glial and 
endothelial cells.  Necrosis and apoptosis are the two major types of cell death observed.  
Apoptosis, or programmed cell death is different from necrosis in that it requires ATP and 
protein synthesis for its execution and forms a characteristic fragmentation that is thought 
to be the result of activation of various proteases, such as caspases and calpains (Porter et 
al., 1999).  Neurons, oligodendrocytes, and astrocytes have all been shown to die from 
apoptosis following TBI (Newcomb et al., 1999).  Necrotic and apoptotic cell death are 
common secondary injury consequences that are seen both in the contusional and 
pericontusional sites, but also in diffuse areas of the brain.  In the rat, the volume of 
cortical contusion and the size of the ventricles increase as time passes post-injury (Smith 
et al., 2000).  Neuronal loss also occurs in diffuse areas such as the hippocampus, and 
apoptotic neurons have been observed in the human hippocampus up to 12 months after 
injury (Williams et al., 2001).  Traumatic axonal injury (TAI- known as DAI in humans) 
results from the acceleration/deceleration forces observed in trauma, in which focal 
alterations in the axolemma lead to progressive changes in axonal transport, swelling and 
eventually delayed or “secondary” axotomy (Grady et al., 1993; Kelly et al., 2006).  
Within 3- to 6-h post-injury, axonal swelling increases to form a retraction bulb and 
ultimately results in axonal separation, depending on the fiber type and size (Povlishock 
and Kontos, 1985; Farkas and Povlishock, 2007).  Therefore, axonal injury can not be 
attributed solely to shearing of axons that occurs at the moment of injury but rather is the 
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result of delayed injury-induced changes within the axon.  One consequence of which is 
downstream deafferntation, or Wallerian degeneration, which may provide an explanation 
not only for the morbidity associated with DAI, but also set the stage for subsequent 
adaptive (or maladaptive plasticity), such as sprouting of adjacent intact nerve fibers and 
functional recovery of neuronal disruption.  The widespread metabolic and neurochemical 
changes that may lead to the pathology observed following TBI will be discussed in more 
detail below.   
Metabolic & Neurochemical Changes 
 The metabolic and neurochemical consequences of TBI involve regional changes as 
well as global abnormalities that change over time.  Identifying specific changes and the 
compounds that are involved allows targeted therapeutic strategies to be developed.  The 
biphasic model of injury, based on work by von Monakow (1969) and Feeney (1991) 
describes the consequences of injury in terms of acute and chronic events (for a review, see 
Whiting and Hamm, 2006).  The biphasic hypothesis in animals describes an acute 
excitation phase lasting approximately 24 h, followed by a chronic depressed phase, lasting 
for weeks or months.  Some of the more important changes and mechanisms are reviewed 
below.     
 The acute stage is characterized by a phase of neuroexcitation, and several studies 
have demonstrated that neuroexcitation following TBI significantly contributes to the 
pathophysiology observed following injury in both animals and humans (Faden et al., 
1989; Hayes et al., 1992; Bullock et al., 1992).  In addition, there is a widespread 
hyperglycoylcis that lasts for a relatively brief period of time post-injury and may be a 
20 
compensatory response to satisfy the heightened cellular energy demand following TBI 
(Yoshino et al., 1991; Jiang et al., 2000; Thomas et al., 2000).  When glutamate, the 
primary excitatory NT in the CNS, activates NMDA receptors, it opens ion channels that 
permit the inflow of calcium and facilitates neuronal depolarization and signal transduction 
(Hayes and Dixon, 1994).  Experimental and clinical evidence suggests extracellular 
glutamate and aspartate are excessively elevated post-injury, which leads to a cascade of 
metabolic disturbances, including the influx of Na+, efflux of K 2+, and subsequent Ca2+ 
influx into the cell (Faden et al., 1989; Katayama et al., 1990; Globus et al., 1995).  The 
changes in Ca2+   homeostasis are believed to play a pivotal role in neuronal cell death.  
Increased intracellular Ca2+ is thought to lead to mitochondrial impairment and the 
induction of apoptotic cell death cascades involving caspaces (Knoblach et al., 2002).  
Likewise, increases in extracellular K 2+   have negative effects and may contribute to 
disruption of energy homeostasis, vasoconstriction, and changes in glycolysis (Siesjo and 
Wieloch, 1985).  Excessive glutamate release can lead to the generation of free radicals 
and proteolytic enzymes, and further release of excitatory amino acids, which eventually 
contributes to cellular edema and the cytotoxic destruction of cells through both direct and 
indirect pathways.  The hippocampus is particularly vulnerable to excitotoxic events, and 
thus, excitotoxicity has been suggested to be one potential explanation for the observed 
cognitive deficits following injury (Temple et al., 2001).  Electrophysiological studies have 
shown that both mild and moderate FPI can suppress LTP in the hippocampal CA1 field 
(Reeves et al., 1995).  In animals, this rise in extracellular glutamate is short-lived, lasting 
less than 24h, however, in humans glutamate concentrations may be elevated for several 
21 
days or perhaps weeks (Baker et al., 1993; Palmer et al., 1994).  Therapeutic strategies 
used in the acute phase have focused on glutamate antagonism to prevent excitotoxicity 
and preserve neurons and axons; however this strategy has met with limited success 
(Tolias and Bullock, 2004).  Other strategies have focused on inhibition of calcium 
channels; however, considerable uncertainty remains over the effects of these drugs 
(Langham et al., 2003).  Acute surges in epinephrine, norepinephrine (NE), dopamine 
(DA) and serotonin (5HT) have also been reported in proportion to injury severity, as well 
as regional changes in the tissue concentration of these neurotransmitters (Prasad et al., 
1992; McIntosh et al., 1994).   Acute elevation of catecholamines is predictive of poor 
recovery following injury.  
Although much research has been dedicated to understanding the mechanisms of 
acute pathology, much less is known about the chronic phase of injury.  In contrast to the 
acute stage, the chronic phase of injury is characterized by widespread neuronal depression 
which includes decreased cellular activity and efficacy (Yoshino et al., 1991).  This period 
of chronic neuronal hypofunction lasts for days to weeks and depends on severity of injury.  
It has been shown that the early hyperglycolytic phase changes to reduced glucose 
metabolism, which lasts until the patient recovers (Bergsneider et al., 2001; Wu et al., 
2004).  Acute surges in neurotransmitters abate with time, and decreases in cerebral 
metabolism are seen in the chronic period post-injury.  Chronic reductions in cholinergic 
function are also reported in both animals (Dixon et al., 1994; Jiang et al., 1994) and 
humans (Arciniegas, 2003).  Catecholamine levels are similarly affected and will be 
discussed in more detail in a subsequent section.   
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The origins of chronic neuronal hypofunction following TBI are uncertain.  
However, it is possible that the dramatic cell loss, axonal damage, and deafferntation from 
both focal and diffuse damage lead to global metabolic effects by disconnecting neurons 
and altering hundreds of circuits.  Post-traumatic neural depression was first described as 
diaschisis, which refers to a state of functional depression in areas remote from the lesion 
(von Monakow, 1914).  Feeney has recently revised this theory and termed it Remote 
Functional Depression (RFD) (Feeney, 1991).  The theory of RFD states that a lack of 
neural input to remote brain regions results in depression of neuronal activity.  Although 
controversial at first, the theory of RFD has been confirmed by measures of blood flow, 
metabolism, electrical activity, and neurotransmitter levels (Meyer et al., 1970; Hovda et 
al., 1987; Yoshino et al., 1991; Baron et al., 1992).  Prolonged depression of neural input 
may result in structural changes in remote brain regions, and may lead to the functional 
impairments seen following brain injury.  Both PET and SPECT assessments of neural 
depression correlate with specific dysfunction in cognitive tasks, in which greater 
depression is directly proportional to the amount of dysfunction (Goldenberg et al., 1992; 
Ricker et al., 2001).  Taken together, the findings from both basic and clinical studies 
support the theory of RFD.     
Other Mechanisms involved in TBI  
   Oxidative damage, manifested primarily as lipid peroxidation, has been 
implicated in many of the pathological changes following TBI (Ercan et al., 2001).  
Following injury, alterations in blood flow without adequate restoration of metabolic 
substrates, as well as other mechanisms such as the initiation of the arachidonic acid (AA) 
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cascade, excessive glutamate release and the increase in intracellular calcium all lead to the 
production of reactive oxygen species (ROS) and AA cascade metabolites (Ikeda and 
Long, 1990).  ROS cause peroxidative destruction to the lipid bilayer of cell membranes 
and the microvasculature, which may affect the BBB integrity (Povlishock and Kontos, 
1992).  They also affect regulatory mechanisms, including activation of cytokines and 
regulation of calmodulin-regulated gene transcription (Yao et al., 1996).  ROS overwhelm 
any endogenous antioxidants and are a key contributor to necrotic cell death and a 
promoter of apoptosis (Kannan and Jain, 2000).  The final products of the AA cascade 
produce pro-inflammatory elements and have been associated with neuronal death and 
poor outcome in experimental TBI (Hall, 1985).  There are also dramatic changes in axons, 
in which it is thought that Ca2+ permeability leads to activated calpains, caspases and the 
formation of ROS which in turn disrupt axonal transport and may lead to axonal collapse 
and detachment (Buki et al., 1999, 2000).  A number of studies have investigated therapies 
that block specific steps in the AA cascade and nitric oxide (Slavik et al., 1999) or use 
antioxidants and free radical scavengers to prevent free radical damage (Shohami et al., 
1997; Marklund et al., 2001; Nakamura et al., 2003).   
Profound changes in the BBB have also been observed in both animals (Povlishock 
et al, 1978) and humans (Soares et al., 1992) following TBI.  The permeability of the BBB 
is usually altered following injury (Povlishock et al., 1978; Cortez et al., 1989), allowing a 
number of foreign proteins and immunocompetent cells found in the plasma, such as 
leukocytes, circulating antibodies, and pro-inflammatory cytokines to enter the brain and 
cause damage through numerous secondary cascades.  The accumulation of leukocytes has 
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been correlated with the onset of lowered CBF, brain swelling, and elevated ICP (Schoettle 
et al., 1990; Zhuang et al., 1993).  There is also an accumulation of macrophages, both 
from glial production and the periphery, which produce soluble factors, including 
cytokines.  Inflammatory cytokines, such as tumor necrosis factor (TNF) and interleukins 
may contribute to the physiological cascades of brain damage following injury, including 
apoptosis and necrosis (Fan et al., 1995; Friedlander et al., 1996).  Several therapeutic 
approaches have focused on blocking these factors with some success.  Cyclosporine A, a 
immunosuppressive compound that inhibits activation of T-lymphocytes, showed some 
success as a neuroprotective agent and improved cognition in experimental studies 
(Alessandri et al., 2002).  More recent strategies have begun to investigate the 
neuroprotective effects of cerebral hypothermia which may protect the vasculature and 
prevent secondary cascades, however, a controlled clinical trial did not find any evidence 
of benefit and thus many questions remain (Suehiro and Povlishock, 2001; Clifton et al., 
2001). 
Mechanisms of Neural Recovery  
A large and increasing number of studies have demonstrated the ability of the brain 
to adapt to the dramatic changes of injury, with changes in functional and structural 
reorganization including dendritic and axonal sprouting, synaptogenesis, neurogenesis, 
altered synaptic activity, and recruitment of parallel pathways (Schallert et al., 2000; 
Scheff et al., 2005; Richardson et al., 2007).  These changes, referred to as plasticity, may 
serve an adaptive role in recovery or maladaptive role, depending on the type and severity 
of injury.  The scope of these compensatory mechanisms, their time course of presentation, 
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and their relationship to injury severity and recovery of function are not well understood, 
however, several studies are beginning to investigate these mechanisms and search for 
therapeutic strategies to enhance these endogenous responses.  Three major physiological 
responses that are involved in the recovery of function are compensatory neuronal 
sprouting to restore lost synapses, the proliferation and differentiation of new cells, and 
biological modifications to modify the efficacy of existing synapses and reverse diaschsis.   
Glia and the extracellular matrix both play an important role in the modulation of 
neuronal activity and synaptic plasticity (Horner and Palmer, 2003; Dityatev and 
Schachner, 2003).  Glia, by releasing NTs and other extracellular signals can affect 
neuronal excitability and synaptic transmission.  Glia, essentially communicate with other 
glial cells through gap junctions, allowing for a glial network that interacts with neurons 
(Haydon, 2001).  Following injury, the blood brain barrier (BBB) is disrupted and the 
microglial response is initiated, stimulating the proliferation of astrocytes.  Reactive 
astrocytes help build a glial scar, which may serve to repair the BBB and limit cellular 
degeneration.  However, despite its protective effect, the formation of a glial scar, which 
consists mainly of reactive astrocytes and proteoglycans, specifically chondroitin sulphate 
proteoglycans (CSPGs), is one of the major barriers to successful regeneration.  Although 
the potential for axonal sprouting may be limited by the post-injury cellular environment, 
lesion studies have demonstrated axons from nearby neurons are able to sprout to nearby 
synapses and reinnervate denervated zones, and thus strengthen or reorganize previously 
existing connections (Selzer, 2003; Dancause et al., 2005).  For example, following 
entorhinal cortex lesions (ECL) sprouting fibers have been found arising from contralateral 
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entorhinal cortex (Deller, 1996), commissural/associational projections, mossy fibers 
(Steward, 1992), septo-dentate projections, and central noradrenergic fibers in the dentate 
gyrus (Peterson et al., 1994).  In addition, lesioned corticospinal tract axons can sprout into 
the intact grey matter and establish novel circuits with long spinal neurons that bypass the 
lesion site (Bareyre et al., 2004).  Therapeutic approaches aimed at these processes have 
attempted to enhance the endogenous plasticity response by counteracting CNS growth-
inhibitory components, specifically CNS myelin proteins (e.g. NOGO-A, MAG) and 
extracellular matrix components (Bushli and Schwab, 2005; Falo et al., 2006). 
Following brain damage, there is a release of various growth-promoting factors and 
growth inhibitory factors which create a unique cellular milieu.  Growth factors such as 
brain derived growth factor (BDNF), nerve growth factor (NGF), and fibroblast growth 
factor (FGF) are all affected at various time points post-injury (DeKosky et al., 1994; 
Hicks et al., 1999).  These growth factors all function in the normal brain to support 
neuronal survival, increase sprouting of neurites, and facilitate the growth of neurons to 
their appropriate targets (Huang and Reichardt, 2001); therefore, increases in these growth 
factors may be important for regeneration and neurogenesis following TBI.  Neural 
depression following brain injury may affect the levels of these neurotrophins as is seen in 
other disorders (Schmidt and Duman et al., 2007).  Studies have suggested that 
neurotrophin expression is regulated by neuronal activity (Zafra et al., 1990; Thoenen, 
1995), and vagus nerve stimulation therapies, as well as drugs that increase norepinephrine 
have been shown to increase levels of neurotrophins (Follesa et al., 2007; Calabrese et al., 
2007).  Neurotrophic factors interact with a number of effectors, such as cAMP, which 
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may help to overcome inhibitory actions of growth-inhibitory proteins (Cui, 2006).  
Numerous studies have demonstrated that neurotrophin treatments following injury have 
positive effects on axonal regeneration and cell survival (Saatman et al., 1997; Yoshimura 
et al., 2003).  One growth factor treatment hat has gained recent support is erythropoietin 
(EPO). EPO has been shown to be neuroprotective and to stimulate angiogenesis, 
neurogenesis, and increase the levels of other growth factors (Shein et al., 2008).  Thus it 
appears that growth factors and treatments that influence their expression have the 
potential to influence outcome at multiple levels.   
The adult brain also contains neural stem cells that have the potential to 
differentiate into neurons, astrocytes, and oligodendrocytes (Song, et al, 2002; Galli et al., 
2008).  Neurogenesis, or the process of functional integration of new neurons, has been 
demonstrated in the adult brain, specifically in the subventricular zone (SVZ) and the 
subgranular zone of the dentate gyrus (Eriksson et al., 1998).  Following experimental 
injury in LFP and CCI models, cell proliferation becomes dramatically increased in the 
hippocampus as early as 2 days post-injury and gradually returns to baseline by day 35 
(Sun et al., 2005; Urrea et al., 2007).  Furthermore, it appears that most of the proliferating 
cells in the DG differentiate and become neurons, some of which receive synaptic input 
(Kernie et al., 2001; Sun et al., 2007).  Moreover, mRNA levels of several cell cycle genes 
and markers for neuronal progenitor cells were up-regulated in the cortex and hippocampus 
following experimental injury (Rall et al., 2003).  It is tempting to speculate that these 
changes may represent an attempt by the brain to replace lost neurons and create new 
functional circuits, however, it is well known that there are many blockades including the 
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glial scar formation and inflammatory processes that may limit neural recovery.  Still, 
therapeutic treatments aimed at manipulating the environment to create a more favorable 
milieu for neurogenesis offers hope as a therapeutic treatment following injury.   
Finally, synaptic reorganization also occurs through strengthening of existing 
connections and an attempt to increase neuronal activity.  The CNS has many redundant 
pathways, and thus when a primary pathway is destroyed or lost to injury, a secondary 
pathway may acquire increased importance (Stroemer et al., 1995).  There also may be an 
unmasking of silent synapses, which is to say if a primary afferent is lost, other “silent”, or 
secondary, afferents may become more important (Blitz et al., 2004).  Changes in receptors 
following injury may be another mechanism used to compensate for the loss of inputs in 
order to increase synaptic efficacy.  Therapies aimed at these processes include 
environmental enrichment and physical therapy to enhance experience-driven relearning 
(Hoffman et al., 2008), and various stimulant and neurotransmitter therapies to increase 
brain activation and reverse RFD.  Norepinephrine, in particular, has been suggested to 
play a major role in the development of diaschisis and if resolution of metabolic depression 
is a form of brain plasticity, it appears to require an optimal catecholamine environment 
(Feeney et al., 1988).   
Pharmacological Approaches to Treatment of TBI 
  This chapter has reviewed some of the mechanisms of brain injury and neural 
recovery, highlighting various therapeutic treatments being investigated following brain 
injury.  The acute stages have focused on neuroprotective agents to protect cells and axons 
by preventing extensive secondary damage.  Treatment of chronic cognitive impairments 
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following brain injury has focused on neurorehabilitation, including a combination of 
restorative or compensatory approaches to enhance plasticity and neural reorganization and 
restore functional outcome.  The complexity of TBI pathology may require a combination 
of many therapies that are given at different time points.  In addition, outcome is highly 
dependent on both the type and severity of injury.  Therefore it is important to have many 
options for therapeutic intervention. 
 Pharmacological agents that target neurotransmitter dysfunction have commonly 
attempted to compensate for the TBI-induced changes in these systems.  Careful 
consideration of the time course of these TBI- induced changes and the timing of treatment 
are important to avoid adverse side effects.  The differences in activity and metabolism 
between the acute and chronic stages are crucial to understand when developing potential 
pharmacological treatments to facilitate functional recovery (Figure 1. The Biphasic 
model).  According to the biphasic model, interventions targeting the chronic phase of TBI 
should be designed to increase neuronal activity to previously normal levels.  Treatments 
that are effective in the acute phase may be detrimental when administered in the chronic 
phase (Hamm et al., 1993).  For example glutamate antagonists administered in the acute 
phase to reduce neuronal activity and prevent secondary damage, are detrimental if 
administered in the chronic stage, when glutamate agonists or drugs that increase neuronal 
activity are favored (Phillips et al., 1999).  Drugs that exacerbate neural depression 
following injury, such as haloperidol or GABA antagonists, also delay recovery (O’Dell et 
al., 2000; Wilson et al., 2003).  Targeting neural depression for therapeutic treatments also 
has advantages in that it affords an extended window for initiating treatment, allowing 
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physicians to initially focus on stabilization of patients.  It is also measurable with imaging 
techniques, and able to be correlated with behavioral deficits. 
Pharmacological treatment with neurotransmitters in the chronic stages has focused 
on cholinergic and catecholaminergic treatments.  The rationale for treatment is based on 
evidence that multiple NT pathways are disturbed following injury and therefore, 
treatments that have known effects on these systems may have an important role in 
facilitating recovery.  In addition, many of the neurobehavioral symptoms that are present 
after TBI show considerable resemblances to symptoms in other neuropsychiatric 
conditions, such as attention-deficit/hyperactivity disorder (ADHD), Alzheimer’s disease, 
alertness in narcolepsy, and mental speed of processing seen in many conditions.  
Therefore, treatments that are normally used to treat these conditions may have some 
benefit in the TBI population.  The catecholamines have also been suggested to be 
beneficial for promotion of recovery from coma and minimally responsive states, although 
there has been little research in this area (Giacino and Trott, 2004).   Although there 
appears to be some benefit from drug treatment, many clinical questions remain such as: 
Which patients will respond favorably to treatment with these agents? Which cognitive 
functions may be facilitated? What is the optimal dose?  When should treatment be 
initiated and for how long?  What is the duration of effect?  Answering these questions 
helps to elucidate the potential mechanisms of these drugs, and leads to a better 
understanding of when these drugs should be used.   
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Figure 1.  A diagram of the biphasic model for treatment following TBI.  Neuronal 
activity is increased during the acute stage, followed by a sustained chronic neuronal 
depression lasting for weeks or months post-injury.  Acute interventions should decrease 
neuronal activity, whereas chronic or subacute interventions should aim for increasing 
neuronal activity.  Successful treatments in the chronic stage should return neuronal 
activity to near baseline or uninjured levels. 
 
 
 
 
 
 
 
 
 
 
 
32 
 
 
 
 
     
 
 
 
 
 
33 
The Catecholamines: Norepinephrine and Dopamine 
Norepinephrine 
Norepinephrine, Receptors & The Norepinephrine Transporter 
 
Norepinephrine (NE) is a neurotransmitter found in the central nervous system and 
biosynthesized from the amino acid tyrosine, which is decarboxylated to produce 
dopamine, and hydroxylated to form NE (Axelrod, 1974).  NE plays an important role as a 
neuromodulator in the adult CNS and has been implicated in attention/arousal, mood 
regulation, sleep regulation, depression, anxiety and aspects of memory.  The central 
noradrenergic system has two distinct projection sites: those originating from the lateral 
tegmental noradrenergic cells, which are implicated in sexual and feeding behaviors, and 
those originating from the locus ceruleus (LC), which are implicated in cognition.  The LC 
resides in the pons and fibers from these cell bodies project to wide areas of the brain 
including the cortex, hippocampus, thalamus, limbic system, and cerebellum.  NE 
innervation appears to be nonjunctional, that is to say NE receptors are far more widely 
distributed than their nerve terminals, and the NE receptor distribution does not resemble 
the pattern of NE fiber distribution.  Two types of LC-derived axonal terminals have been 
described: conventional synaptic structures and nonsynaptic varicosities.  The later are 
believed to release NE extrasynaptically allowing for its diffusion over some distance in the 
microenvironment before it may act on surrounding neurons, glial cells, and blood vessels 
(Marien et al., 2004). 
  NE interacts with three families of adrenergic receptors: the α1, the α2 and the β 
adrenergic receptors.  Because of their mechanism of action, these receptors are referred to 
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as G-protein-coupled receptors.  The binding of NE induces a conformational change that 
allows the receptor to interact with and activate a G protein, which in turn leads to the 
dissociation of the α and βγ subunits and downstream stimulation or inhibition of various 
effectors.  α1 receptors are generally coupled to Gq proteins that activate phospholipase C 
and phosphotidyl inositol intracellular signaling, resulting in activation of protein kinase C 
(PKC) and the release of intracellular calcium via inositol 1, 4, 5-triphosphate (Duman & 
Nestler, 1995; Birnbaum et al., 2004 ).  Activation of α1-adrenergic receptors leads to up-
regulation of CREB-mediated gene transcription.  α2 autoreceptors are generally found 
presynaptically and are coupled to Gi proteins (Duman & Nestler, 1995; Ramos et al., 
2006), which can reduce intracellular cAMP production by inhibiting adenylyl cyclase.  
Both α1, α2 receptors are found throughout the cortex, however, only certain subtypes of 
these receptors are found within the hippocampus (Winzer-Serhan and Leslie, 1997).         
β -adrenergic receptors are primarily located in the cortex, nucleus accumbens and 
striatum, with lower, yet significant densities in the amygdala and hippocampus.  These 
receptors are found in postsynaptic sites on DG granule cells and interneurons as well as in 
glial processes in the hippocampus (Guo and Li, 2007).  They are also found primarily 
postsynaptically on dendritic spines, GABAergic neurons, and glia in the frontal cortex 
(Aoki et al., 1998).  There are three β-adrenergic subtypes (β1, β2, and β3), and all are 
positively coupled to adenyl cyclase via activation of Gs (Pupo and Minneman, 2001).  β -
adrenergic receptor activation of cAMP results in stimulation of PKA.  PKA can 
phosphorylate and activate CREB and other transcription factors, leading to altered 
regulation of gene expression.  CREB is expressed throughout the brain and is involved in 
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synaptic plasticity and other cellular functions in many brain regions.  Studies suggest that 
memory consolidation and memory retrieval by the hippocampus may be dependent on 
beta-adrenergic activity and cAMP-PKA signaling (Arnsten et al., 2005; Korz, 2007).  
This evidence taken together suggests central β-adrenoceptors are involved in neuronal and 
behavioral plasticity (Berridge et al., 1996).      
 The norepinephrine transporter (NET) is located on the plasma membrane of 
noradrenergic neurons where it functions to reuptake NE from the synapse into the 
presynaptic terminal, therefore terminating and limiting the action of this neurotransmitter.  
The NET not only regulates the longevity of NE in the synapse but also plays a very 
important role in presynaptic and postsynaptic homeostasis (Zhou, 2004).  Studies using 
NET-deficient mice, have found profound changes in NE homeostasis and synaptic 
plasticity, suggesting a role for the NET in these processes (Xu et al., 2000).  NETs also 
transport other catecholamines, including DA and epinephrine. Strong NET expression is 
found globally throughout the brain including such areas as the adult cortex, hippocampus, 
thalamus, and amygdala, correlating with areas of dense NE innervation (Sanders et al., 
2005).  There are also high levels of NET found in the LC and DA-rich areas such as the 
ventral tegmental area (VTA) and PFC, in which the NET also contributes to the clearance 
of DA in these brain regions.  The NET has also been found on astrocytes and 
endothelium, suggesting a role for these cells in regulation of NE (Inazu et al., 2003).  
Given that NET’s control the spatial and temporal aspects of NE action, modulation of 
NET activity would be expected to influence NE neurotransmission.  Selective or mixed 
monoamine transporter inhibitors have been developed to treat a variety of disorders 
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including mood disorders, personality disorders, depression, Alzheimer’s disease, chronic 
pain, migraine, stroke and trauma (Van Moffaret et al., 1999; Olivier et al., 2000; Wong et 
al., 2000; Zhou et al., 2003).   
NE and Cognition 
The noradrenergic system is a well-known modulator of neuronal activity and has 
been implicated in many aspects of brain function, including vigilance, arousal, attention 
and aspects of learning and memory (Aston-Jones et al., 1991; Cole and Robbins 1992; 
Berridge 1993).  NE has been termed both a neurotransmitter and a neuromodulator.  NE 
projections from the LC innervate the entire neuroaxis, positioning this NT to enact global 
state-change functions and influence the outcome characteristics of the brain when NE is 
elevated.  The cellular effects of NE are modulatory in nature, altering the “signal-to –
noise” activity in circuits and allowing synaptic transmission to be more effective, and thus 
presumably enhancing cognition and behavioral responses in brain areas innervated by NE 
(Woodward et al., 1991).   
The NE projections to the frontal cortex are important for mechanisms of attention 
and arousal, as well as working memory.  Elevating central NE activity, through α2-
adrenergic autoreceptor antagonists or NET inhibitors, improved performance in tasks 
assessing attention and working memory (Bunsey and Strupp 1995;   Sagvolden and Zu 
2008), whereas reduced NE transmission had deleterious effects on attention (Smith and 
Nutt 1996).  Depletion of forebrain NE in rats leads to distractibility and attentional 
deficits in a variety of paradigms (Carli et al., 1983; Cole and Robbins, 1992).  
Furthermore, NE receptor blockade induced a state of sedation and behavioral inactivity.   
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The hippocampus has one of the denser regions of adrenergic terminals, supporting 
the role of NE in learning and memory in this region (Korz, 2007).  NE innervation is 
particularily dense in areas receiving mossy fiber inputs, including the dentate gyrus and 
stratum lucidum (Moudy et al., 1993).  Several studies have demonstrated the importance 
of NE signaling for consolidation of emotionally laden events, especially for aversively 
trained animals, which may involve the amygdala and hippocampus (Ferry and McGaugh, 
2000).  Other studies have begun to investigate a role of NE in spatial navigation tasks and 
have found that NE is important for consolidation and retrieval of spatial memories 
(Murchison et al., 2004; Korz, 2007).  Animals with reduced cortical NE levels performed 
significantly worse in the spatial memory task of the MWM compared to matched controls 
(Collier et al., 2004).  Enhancing NE tone prior to retention testing showed significantly 
less “forgetting” in a spatial memory task of the MWM (Sara et al., 1989).  
NE mechanisms may also play an important role in neuroplasticity in the 
hippocampus.  Considerable evidence indicates NE increases the signal- to- noise ratio by 
inhibiting neuronal background firing and enhancing responses to significant stimuli.  In 
vitro studies in cortical and hippocampal slices show that NE depletion reduces or 
eliminates LTP (Harley, 1998), whereas NE agonists increase LTP (Izumi et al., 1999). 
There is considerable evidence to suggest NE manipulations can modulate early LTP in 
several hippocampal pathways (Munro et al., 2001; Harley, 2008).  These mechanisms 
have focused on beta-adrenergic receptors. For example, NE enhances LTP in the mossy 
fiber-CA3 synapse via beta-adrenergic mechanism, and pharmacological activation of 
beta- adrenergic receptors can rescue CA1 LTP in genetic strains with impaired LTP 
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(Schimanski et al., 2007).  NE in the dentate gyrus permits long-term perfornat path 
potentiation, and phasic LC activation produces delayed protein synthesis-dependant LTP 
of synaptic plasticity (Dahl and Sarvey, 1989).  Activation of the LC causes a slow onset 
LTP in the dentate gyrus, and adrenergic agonists result in the conversion of early LTP to 
protein-dependent late LTP in CA1 and the dentate gyrus (Harley, 2007).  Finally, 
depletion of NE and destruction of NE terminals results in a dramatic acceleration in the 
rate of seizure development with electrical stimulation of limbic or cortical structures 
(Lewis and Westerburg, 1987).  Therefore, NE plays an important role in maintaining 
excitatory/inhibitory homeostasis and influences synaptic plasticity.   
Finally, a number of disease states show alterations in NE neurotransmission.  In 
aged animals, even a small degree of LC cell loss correlates strongly with impaired 
memory (Leslie et al., 1985).  Furthermore, electrical stimulation or pharmacological 
activation of the LC protects from age-related memory loss (Birthelmer et al., 2003).  NE 
has been theorized to play a role in the progression of Alzheimer’s disease (for a review, 
see Marien et al., 2004).  This theory may be related to the interactions between NE and 
acetylcholine in the brain.  There are many overlapping terminal fields, where these 
neurotransmitters may influence each other, including the basal forebrain (Zaborszky et al., 
1993).  The interactions between these NTs may also explain why drugs that increase 
extracellular levels of NE also tend to increase acetylcholine levels (Tzavara et al., 2006).  
Even more interesting, are the studies that have found the appearance of ingrowth of NE 
fibers and increases in NE concentrations in the hippocampus following cholinergic lesions 
(Harrell et al., 2005).  This study suggests peripheral adrenergic sprouting and 
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hippocampal ingrowth can be neuroprotective and may be able to replace the central 
cholinergic system in terms of function. 
NE has also been thoroughly investigated in the context of ADHD.  Several recent 
studies, suggest that NE may be even more important that DA, particularly in regards to 
treatment (Biederman et al., 2000).  In addition, NE has also been hypothesized to play an 
important role in stress and depression, and has been implicated in the effects of 
antidepressant drugs (Laifenfeld et al., 2005).  Depression and stress have been associated 
with impairments of structural plasticity (Fuchs et al., 2004), and studies have found 
antidepressant treatments, which increase NE and 5-HT, induce increases in protein kinase 
C (Morishita and Aoki, 2002), calcium-linked protein kinases (Consogno et al., 2001) 
protein kinase A (Nestler et al., 1989). It is hypothesized that these changes lead to 
increases in CREB and changes in gene expression, including an increase in neurotrophic 
factors.  These changes may account for the clinical success of antidepressants and explain 
why there is often a delay between initiation of antidepressants and observed clinical 
effects.  In contrast, too much NE has been linked to the symptoms of mania, 
schizophrenia, and PTSD.  The evidence taken together highlights the delicate balance 
between catecholamine levels and disease states, where too much or too little can cause 
various levels of dysfunction. 
Norepinephrine and Mechanisms Important to TBI 
 Apart from the role of NE as a neurotransmitter, NE may influence the survival, 
maintenance and plasticity of CNS neurons (including the regulation of neurotrophins), 
glial functions, and inflammatory responses.  NE has been hypothesized to play a role in 
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neurogenesis in both the subventicular zone and the hippocampus.  Following, dexefaroxan 
treatment (which increases NE release) cell proliferation, assessed by BrdU labeling, was 
significantly increased relative to saline treated controls in the olfactory bulb, while 
apoptotic cell death was decreased ( Veyrac et al., 2005).  In the hippocampus, NE 
depletion was found to affect the proliferation of adult hippocampal granule cell 
progenitors (Kulkarni et al., 2002), while, treatment with dexefaroxan, which increases NE 
activity, increased the survival and differentiation of new hippocampal granule cells, but 
had relatively no effects on proliferation (Rizk et al., 2006).  NE also been suggested to 
have effects on neurotrophins such as brain-derived gowth factor (BDNF) and nerve 
growth factor (NGF), which could influence these processes (Fawcett et al., 1998; Garcia 
et al., 2003; Ivy et al., 2003).  For example, NE increases production of BDNF in cultured 
astrocytes (Juric and Carman-Krzan, 2006).  Desipramine treatment, as well as other 
antidepressants that affect the levels of NE, have been shown to increase expression of 
CREB mRNA and protein in the hippocampus (Nibuya et al., 1996).  Other studies have 
found desipramine also increases the levels of both BDNF and its receptor TrkB (Nibuya 
et al., 1995; Conti et al., 2002).  Furthermore, selective NE reuptake inhibitors have been 
shown to increase adult neurogenesis and phosphorylated CREB (Duman et al., 2000).  
While the mechanisms underlying these effects are not completely understood, it does 
suggest NE pharmacology may influence neural recovery through enhancing post-injury-
induced plasticity. 
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Dopamine 
Dopamine, and Dopamine Receptors 
 Dopamine is the other catecholaminergic neurotransmitter that serves a 
neuromodulatory role in the CNS.  Dopamine is synthesized in the cytoplasm of 
dopaminergic neurons from the precursor L-DOPA.  Tyrosine hydroxylase is the rate-
limiting enzyme in the synthesis of both DA and NE.  The DA transporter (DAT), located 
in the presynaptic membrane serves to reuptake DA into the membrane to be re-used or 
metabolized by monoamine oxidase (MAO).  DA neurons originate from the ventral 
tegmental area (VTA) and substantia nigra pars compacta (SNC) and play a critical role in 
behavioral functions ranging from motor planning to cognition (Bjorklund and Lindvall, 
1984).  There are three main DA pathways-the nigrostriatal projections from the SNC to 
the basal ganglia, the mesolimbic pathway between VTA and limbic striatum, and the 
mesocortical pathway from the VTA to the to the frontal, cingulate, and hippocampal 
cortices (Bjorklund et al., 1984).  The frontal cortex receives the majority of VTA DA 
projections in the rat, and in turn, receives excitatory projections from the PFC (Van Edyn 
et al., 1987).  The nucleus accumbens and amygdala receive dopaminergic innervation 
from the VTA, which are thought to facilitate reward-seeking and emotional behavior 
(Groenewegen and Uylings, 2000).  Cortical DA projections to the frontal cortex play a 
role in cognitive processes including working memory and motor planning (Sawaguchi and 
Goldman-Rakic, 1994).  The dorsolateral prefrontal cortex receives a large amount of DA 
projections that are thought to be involved in is involved in attention, initiative, motivation, 
planning, decision making, working memory, and other higher order cognitive functions.  
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The VTA also send DA projections to the CA1/subiculum area of the hippocampus, which 
are thought to have a role in suppressing hippocampal excitability and/or novelty detection 
(Gasbarri et al., 1997). 
 Dopamine interacts with five receptor subtypes (D1-D5).  All five are slow 
metabotrophic receptors that modulate other ion channels and receptor systems.  In both 
rats and humans, DA receptors are found in the caudate-putamen, nucleus accumbens, 
olfactory tubercle, substantia nigra, periventricular nucleus of the hypothalamus, dentate 
gyrus, and the endopiriform cortex.  D1 and D5 receptors are members of the D1-like 
receptor family, and the others are members of the D2-like receptor family.  D1-like and 
D2-like receptors play opposing regulatory roles.  D1 receptor activation activates cAMP 
or IP3 second messenger pathways and leads to intracellular signaling cascades involving 
PKA, phosphorylation of DARP32, and inhibition of protein phosphatase-1, and ultimately 
leads to activation of CREB, and transcription of immediate early genes (IEG) and late 
response genes (LRG) that mediate long term changes in ionic channel strength.  D2 
receptor mediated regulation is more complex, and there are many opposing opinions 
between researchers about the role of these receptors.  D2 receptors suppress cAMP and 
activate platelet derived growth factor (PDGF) initiation of intracellular Ca2+ release, 
which ultimately inactivates NMDA receptors (Surmeier et al., 1995).  In the rat, D1 and 
D2 receptors are found on both pyramidal and non-pyramidal neurons in the frontal cortex, 
however, a larger population of D1 receptors is found in this region (Benes and Beretta, 
2001).  In the hippocampus studies have shown a prominent labeling of D1-like receptors 
dorsally in granular cells of the dentate gyrus and the subiculum, but only a few labeled 
43 
cells in the stratum oriens and radiatum of CA1-CA3 (Fremeau et al., 1991).  Recent 
studies suggest that D5 receptors are the predominant D1-like receptor in this region.  D5 
immunoreactive neurons are localized in the hilus and granular cells of the dentate gyrus, 
in pyramidal cells of the subiculum, but also in CA1 and CA3 (Ciliax et al., 2000; Khan et 
al., 2000).  The distribution of D1 receptors at the subcellular level in the hippocampus 
appears in both pyramidal cells and dendrites (Bergson et al., 1995).  In contrast, low 
levels of D2 receptor mRNA has been detected in the hippocampus (Levey et al., 1993).  
Although it is uncertain exactly how receptor distribution affects cognition, the brain 
clearly has multiple receptors for neurotransmitters.  The types and amount of each 
receptor expressed in different brain regions appears to play an important role in the 
regulation of synaptic plasticity and memory processes. 
Dopamine and Cognition:   
     DA is an important neurotransmitter in many frontal lobe processes such as 
executive functions and working memory.  Lesions of the mesocortical DA projections 
impair working memory in monkeys (Brozoski et al., 1979) and rats (Simon, 1981). 
Behavioral studies have shown that an optimal level of dopamine and D1 receptor 
activation is crucial for delay dependent tasks requiring working memory functions 
subserved by the frontal cortex (Goldman Rakic, 1995).  Experimental studies in rats, 
monkeys, and humans all highlight the inverted U-shaped relationship between DA levels 
and cognition.   
In the hippocampus, the CA1 domain receives DA projections from the VTA that 
terminate predominantly in the SLM, and firing of  these DA neurons in the VTA has been 
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linked with the prediction of motivationally significant events and reward, as well as novel 
events and stimuli (Gasbarri et al., 1997; for review, see Schultz, 2006).  In the 
hippocampus, blockade or knockout of D1/D5 receptors impairs LTP in CA1 (O’Carroll 
and Morris, 2004), and dopamine agonists enhance the magnitude and persistence of CA1 
LTP (Otmakhova and Lisman, 1996).  DA agonists have been shown to enhance memory 
in both spatial and non-spatial tasks (Bach et al., 1999; Bernabeu et al., 1997).  Conversely, 
treatments that decrease hippocampal DA activity impair spatial memory (Gasbarri et al., 
1996).  It is tempting to speculate, that DA activity in response to the reward and novelty 
of locating an escape platform may lead to subsequent stabilization of synaptic changes, 
however, this hypothesis requires significantly more investigation. 
The Catecholamines and TBI 
 Several studies looking at neurochemical changes following TBI suggest that 
alterations in neurotransmitters, including changes in NT production, delivery or both, 
occur within networks both acutely and chronically and may differ depending on  the brain 
region examined ( Hayes et al., 1992; McIntosh et al., 1994).  Experimental models have 
shown NE and DA levels rise in the acute phase, but are depressed in the sub- acute or 
chronic phase (Dunn-Meynell et al., 1994;Levin and Kraus, 1994).  Plasma NE levels are 
elevated in the acute phase after TBI, and this elevation correlates with injury severity 
(Hamill et al., 1987; McIntosh et al., 1994; Schwarz et al., 1997).  Some studies have 
suggested the early increase in NE may be protective and help stabilize the blood-brain 
barrier (Dunn-Meynell et al., 1998), whereas others have suggested NE may facilitate the 
damaging effects of glutamate.  The chronic post-injury state, however, is characterized by 
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a relative decline in NE and DA metabolism (Goldstein, 1999; Donnemiller et al., 2000).  
One study found NE metabolism begins to decrease in the brain between 6h and 24 h after 
injury (Dunn-Meynell et al., 1998).  Another found  a 27% decrease in the size of LC 
neurons in the chronic phase following impact acceleration injury that gradually returns to 
normal over one month (Fujinaka et al., 2003).  The same study confirmed that NE 
neurotransmission is affected beginning around 24-48 h after experimental TBI and 
remains low until eight weeks post-injury.  Therefore, even after cell bodies recover, NE 
turnover may not.  Norepinephrine fiber loss has been reported in the hippocampus 
following central-fluid percussion and the combined FPI+ entorhinal lesion model at 15 
days post injury (Zhu et al., 2000).  Similarly, DA tissue levels have been reported to 
decrease at 1 h. post-injury and remain depressed for up to two weeks following fluid-
percussion injury (FPI) (McIntosh et al., 1994).  Subsequent studies using controlled 
cortical impact (CCI) found cortical DA metabolism was depressed for up to four weeks 
post-injury (Massucci et al., 2004).  DA kinetics, including turnover and release of DA, are 
also affected in the striatum, suggesting a hypodopaminergic state following trauma 
(Wagner et al., 2005).  In addition, DA projections to the medial septal area (MSA) can 
modulate hippocampal acetylcholine release, and TBI has been shown to decrease 
extracellular DA levels.  In humans, tyrosine, the precursor molecule for catecholamine 
production, was significantly lower than normal in TBI patients up to 2 months post-injury 
(Aquilani et al., 2003).  Further studies using fMRI, suggest posttraumatic working 
memory impairments are specifically attributable to noradrenergic dysfunction (McAllister 
et al., 2004).  The results taken together suggest chronic catecholamine hypofunction may 
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be one result of TBI.  Because the catecholamines have a neuromodulatory role in the CNS 
and exercise a facilitating effect on many networks, damage to these neurons and their 
ascending axons could have diffuse effects on a wide range of cognitive functions (Dunn-
Meynell et al., 1994).   
In contrast, some studies have suggested that catecholamine synthesis and tissue 
levels are not depressed in the chronic stage, but actually elevated at one and two weeks 
post-injury ( Tang et al., 1997; Kobori et al., 2006; Yan et al., 2001).  Neurochemical 
disturbances clearly reflect the nature of the injury, as well as the affected brain regions 
(McIntosh, 1996).  Therefore, differences between injury models are likely responsible for 
the conflicting results.  The neuromodulatory neurotransmitters, NE and DA, are 
functionally interrelated and changes in one NT system may be felt downstream in another 
system by influencing neuronal firing rates or the sensitivity of receptors, which is often 
what happens in the development of mood disorders (Stokes et al., 1987).  Therefore, NE 
and DA have been suggested to play a major role in the formation of diaschisis, or RFD 
(Feeney and Sutton 1998).  Still many questions remain, and it is unknown to what extent 
alterations in catecholamine metabolism following TBI represent compensatory 
mechanisms versus changes due to loss of input or other secondary damage which may 
directly contribute to TBI-associated deficits.  While the contributions of catecholamine 
dysfunction to cognitive deficits and the changes in catecholamine metabolism require 
further investigation, the findings from experimental studies do suggest these 
neurotransmitters are reliable targets for pharmacological interventions to improve 
functional outcome.    
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Catecholamine theory of recovery 
 Treatments that act on central neurotransmitter systems have been shown to alter 
recovery following brain injury.  Considerable attention has been given to drugs that affect 
cholinergic and catecholaminergic systems.  Several studies in animals and humans have 
investigated the effects of catecholaminergic agents following experimental and human 
brain injury.  Some of the more pertinent treatments are reviewed below. 
Amphetamine:  Recovery of function after cortical injury, and the maintenance of 
that recovery in both animals and human may depend on the integrity of the noradrenergic 
system.  The beneficial effects of NE following brain injury have been well documented 
for several years.  Considerable evidence indicates pharmacologically enhancing brain NE 
concentrations following injury is beneficial, both at acute time points and at more delayed 
time points. (Feeney et al., 1997; Gladstone and Black, 2000; Goldstein, 2003; McIntosh, 
1993).  Amphetamine (AMP) activates both the NE and DA systems, and there is evidence 
that a single dose of dextroamphetamine (D-AMP) increases the rate of motor recovery in 
experimentally injured rats (Feeney et al., 1982).  Although the exact mechanism of 
amphetamine is unknown, it is postulated to release pools of DA and NE from the locus 
ceruleus (LC) as well as block catecholamine reuptake into the presynaptic terminal 
(Boyeson et al., 1990).  More recent studies using the fluid-percussion model on injury 
found AMP treatment can attenuate increases in lactate and free fatty acids seen after 
injury (Dhillion et al., 1998).  Many subsequent studies have confirmed  the role of  NE in 
cortically injured rats by showing AMP administered 24h after cortical ablation injury 
accelerates motor recovery, as long as it is coupled with beam-walking (Dhillon et al., 
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1998).  It appears that D-AMP induced-recovery in both animals and humans requires co-
training (Gladstone and Black, 2000), suggesting catecholaminergic stimulant treatment 
may serve as a facilitator of the learning experience.  For example, when patients were 
treated with D-AMP paired with physical therapy, they found AMP enhanced the speed of 
recovery and extent of recovery from hemiplegia, which persisted for 1 year after 
discontinuation of the drug (Walker et al., 1995).  Interestingly, studies that failed to 
couple drug regimen and physical therapy did not produce beneficial results (Feeney et al., 
1997).  It also appears therapeutic window is an important factor in D-AMP treatment.  
When treatment with D-AMP was delayed one month, no significant functional benefit 
was found, suggesting a critical window early after injury for treatment (Goldstein et al., 
2003).  These studies in animals provide a convincing role for AMP in motor recovery; 
however, relatively few studies have investigated AMP and cognition following injury.  
Some studies found cognitive function was improved if AMP was administered at 10 min, 
but not at 24h following L-FPI (Dose et al., 1997), suggesting the time period for treatment 
with this drug is limited to time points very early after injury.  D-AMP is sometimes used 
to treat impairments in arousal, speed of processing, attention, and memory in the TBI 
population although the evidence to support its use is sparse (Hornstein et al., 1996).  AMP 
is also a controlled substance with both abuse and addictive potential, which further limits 
the use of this drug in this population.   
 Methylphenidate: Methylphenidate is another stimulant that increases the 
release of both NE and DA, and at higher doses, blocks the reuptake of these NTs.  
Clinically it is indicated for attention deficit disorder to improve attention tasks and mental 
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processing (Malone et al., 1994).  Early studies suggested that methylphenidate may 
improve posttraumatic impairments in arousal, speed of processing, attention, memory, 
mood, and aspects of behavior (Gualtieri et al., 1988; Mooney et al., 1993; Plegner et al., 
1996).  In experimental studies, Kline and coworkers (2000) found chronic 
methylphenidate treatment initiated 24h after Lateral-CCI and continued for 18 days 
resulted in significantly reduced latencies to find the platform in the spatial navigation task 
of the Morris water maze.  Interestingly, this study found no improvement in motor 
function.  These studies suggested methylphenidate may be an effective treatment for a 
range of cognitive dysfunction following injury.  Clinically, however, Whyte and 
coworkers (1997, 2004) demonstrated that the primary benefit of methylphenidate is on 
post-traumatic impairments of processing speed, and to a lesser extent on subjective ratings 
of behavior and mood.  Other clinical studies suggest that although methylphenidate might 
facilitate the rate of recovery, it may not necessarily improve long-term outcome (Plenger 
et al., 1996).  Still, recent guidelines for pharmacologic treatment following TBI suggest 
methylphenidate is recommended to enhance attentional function, and the speed of 
cognitive processing, as well as an option to enhance learning and memory (Warden et al., 
2006).   
L-Deprenyl:  L-Deprenyl is a selective and irreversible monoamine oxidase-B 
(MAO-B) inhibitor used clinically in the treatment of Parkinson’s disease (Kieburtz et al., 
1994).  L-Deprenyl has been shown to protect hippocampal pyramidal cells from ischemic 
damage and improve cognitive performance of aged rats (Knoll, 1993).  Following 
experimental brain injury of moderate severity, chronic L-Deprenyl treatment for 7 days 
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post-injury significantly reduced cognitive deficits in the spatial navigation task of the 
MWM on days 11-15 and decreased catecholaminergic fiber loss in the hippocampus (Zhu 
et al., 2000).  By terminating drug treatment before MWM testing, this study suggests 
augmenting NE and DA levels may have long-term effects on functional outcome.   
However, the mechanism is uncertain and may be related to L-Deprenyl’s effects on 
oxidative free radicals or enhanced synthesis of growth factors, rather than augmenting 
catecholaminergic neural transmission.  A recent case study in 4 patients shows L-
Deprenyl has potential for the management of apathy following TBI (Newburn and 
Newburn, 2005). 
Amantadine and Memantine:  Amantadine and memantine are non-competitive 
NMDA receptor antagonists; however, there effects following injury appear to be more 
related to their ability to increase DA release, stimulate dopamine receptors and/or enhance 
postsynaptic dopamine receptor sensitivity (Page et al., 2000; Peeters et al., 2003, 2004).   
Amantadine treatment, initiated 24h after injury and continued for 18 days, has been 
shown to improve performance in the MWM spatial task (Dixon et al., 1999).  Clinically, 
Nickels et al., found amantadine improved attention, concentration, arousal, speed of 
processing, agitation and anxiety in patients (1994).  Meythaler et al. (2002), in a double-
blind, placebo controlled randomized trial, found significant improvements in functional 
outcome after six weeks of treatment.  Other studies in the brain injured population have 
found significant improvements in executive functioning, agitation, and subjective 
cognitive improvements (Kraus et al., 1997; Zafonte et al., 1998).  Memantine has 
gathered some interest from the TBI community; however, at present there are no studies 
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regarding the use of this treatment for posttraumatic cognitive deficits.  Preliminary studies 
in patients with dementia suggest memantine may have some benefit for treating dementia 
and may contribute to behavioral modification (Orgogozo et al., 2002).  Future studies are 
needed to examine its efficacy and safety in brain- injured patients.  
Other NE and DA Augmentation Strategies 
  Many DA agonist therapies have been shown to attenuate the deficits associated 
with frontal lobe syndrome (McDowell et al., 1998).  Chronic bromocriptine, a D2 
Receptor agonist, initiated 24h after CCI injury improved both working memory and 
spatial acquisition in the MWM (Kline et al., 2002).  Bromocriptine also improved 
histological outcome in CA3 of the hippocampus.  Some antidepressants, which inhibit NE 
reuptake, have been shown to improve the recovery process (Boyeson and Harmon, 1993). 
In humans, amitriptyline, desipramine, and protiptyline have all been suggested to improve 
recovery in some TBI patients (Reinhard et al., 1996; Boyeson and Harmon, 1993).  In 
addition, intrarventricular infusion of NE or the NE and DA precursor L-DOPA, co-
administered with carbidopa, facilitates recovery (Kikuchi et al., 2000).  Conversely, drugs 
that antagonize catecholaminergic transmission, such as haloperidol were found to slow 
functional recovery (Feeney et al., 1982; Wilson et al., 2003).   
 The mechanisms through which noradrenergic pharmacotherapy improve 
functional recovery are unknown.  Resolution of diaschisis and enhancement of brain 
plasticity have been proposed, including unmasking of latent connections, axonal 
sprouting, and recruitment of alternative pathways (Gladstone and Black, 2000; Feeney, 
1997).  Norepinephrine depletion may affect many aspects of brain plasticity following 
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TBI including sprouting of axons and dendrites, new receptor generation, and 
enhancements in connections due to stimuli.  Amphetamine and drugs that increase NE 
have been shown to facilitate plasticity, neurogenesis, and neurotrophin increases 
(Stroemer et al., 1998; Malberg et al., 2000; Butefisch et al., 2002), whereas decreasing NE 
pharmacologically decreases BDNF and plasticity associated with exercise (Garcia et al., 
2003).  The plasticity-promoting effects of NE, may be due to the cooperative actions of 
NE with other neurotransmitters, neurotrophins or immediate early genes (p-CREB c-fos) 
(Marien et al., 2004; Laifenfeld et al., 2002).  Two important considerations appear to be 
the dose dependence and timing of drug administration, as well as task-relevant 
experience.  
 The therapeutic benefits observed with DA agonists following TBI also 
implies a role for DA in post-injury cognitive deficits.  The potential mechanism of DA-
enhanced recovery following trauma may be attributed to the role of DA in maintaining 
both excitatory and inhibitory homeostasis.  DA receptor signal transduction pathways are 
complex, but both NMDA and AMPA glutamate receptors can be modulated by DA 
(Sutton and Schuman, 2005).  In cultured hippocampal cells, Sutton and colleagues (2005) 
demonstrate that D1-like receptor activation leads to increases in protein synthesis, 
specifically AMPA subunit GluR1.  DA acting through D1-like  receptors, increases 
intracellular cAMP and activates PKA, which leads to numerous downstream targets 
including voltage-and ligand-gated ion channels, CREB, and a number of proteins 
involved in signal transduction and gene regulation (Neve et al., 2004).  Other studies have 
suggested DA agonist therapy reduces oxidative stress, and has antioxidant like 
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characteristics (Kline et al., 2004).  The different clinical effects of DA agonists in post-
injury treatment may be explained on the basis of their differential actions on specific 
classes of DA receptors (e.g., D1-like or D2-like, presynaptic versus postsynaptic, and 
excitatory versus inhibitory) and may have different effects in various brain regions.  
Although pharmacological enhancement of NE and DA following TBI has yielded positive 
results in animals and humans, the precise mode of impairment on these NT systems is not 
fully understood and more experimental studies are needed to access the effects of these 
agents following TBI.  Many questions about drug safety, the most efficacious dose, when 
treatment should be initiated to be effective and discontinuation still remain to be 
investigated more thoroughly. 
 
Atomoxetine 
Atomoxetine  [ (-)-N-methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride] 
is a selective norepinephrine transporter (NET) inhibitor approved by the FDA for the 
treatment of symptoms of Attention Deficit/Hyperactivity Disorder and co-morbid 
symptoms of depression and anxiety (Pataki et al., 2004).  Atomoxetine shows a high 
selectivity for the presynaptic NET, with a low affinity for other monoamine transporters 
(Gehlert et al., 1993).  The in vitro affinity of atomoxetine for NET is 5nM (Ki value), and 
the affinity is 15 and 290-fold lower for 5-HT and DA transporters (Bymaster et al., 2002).  
Atomoxetine also has a minimal affinity for other neurotransmitter transporters and 
neuronal receptors (Gehlert et al., 1995).  PET studies demonstrated that atomoxetine 
occupies the NET in a dose-dependent and saturable fashion (Seneca et al., 2006).  The 
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primary mechanism of action of atomoxetine is thought to be inhibition of the reuptake of 
NE into the presynaptic terminal.  The clinical efficacy is thought to result, at least in part, 
from increased synaptic concentrations of NE and the postsynaptic adaptations that ensue.  
In a rodent model, atomoxetine also increased extracellular levels of DA levels in the 
frontal cortex (Bymaster et al., 2002).  DA reuptake by the NET occurs  in select regions of 
the brain, such as the frontal cortex, where low densities of the DA transporter are found 
(Moron et al., 2002).  The increase in DA is not observed in the striatum or nucleus 
accumbens.  Therefore, unlike psychostimulants that are associated with addictive potential 
due to effects on the midbrain dopamine system, atomoxetine appears to lack these effects 
and to have low addictive potential.  Other clinical advantages are emerging, such as 
benefits for sleep quality over psychostimulants and possible efficacy in the treatment of 
comorbid tics. 
In humans, atomoxetine has a half-life of approximately 5 h, and it is primarily 
eliminated by oxidative metabolism.  Maximal concentrations of atomoxetine are reached 
in the plasma between 1 and 2 h.  Although atomoxetine has been well characterized in 
humans, relatively few studies have looked at the pharmacokinetics and 
pharmacodynamics in animals.  One study in Fisher rats found the distribution and 
elimination half-lives of atomoxetine following intravenous administration were .09 and 
1.4 h, respectively, with a longer residual phase lasting between 12-24 h (Mattiuz et al., 
2003).  The same study found there was low bioavailability following oral administration 
in the rat, suggesting this form of drug delivery should not be used in rodent studies.  The 
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primary circulating plasma metabolite is 4-hydroxyatomoxetine-O-glucuronide, and no 
reactive intermediates or electrophilic species have been found.    
Atomoxetine has positive effects on cognition using various behavioral paradigms 
in animals.  Using a 5-choice serial reaction time task, low doses of atomoxetine treatment 
significantly reduced impulsivity and improved overall attention (Navarra et al., 2008).  In 
animals, atomoxetine is effective at suppressing motor hyperactivity and improving 
attention in a model of ADHD (Moran-Gates et al., 2005).  Atomoxetine also improves 
performance in two animal models of memory, the object recognition test and the radial 
arm-maze test (Tzavara et al., 2006).  Recent studies confirm that atomoxetine increases 
cholinergic neurotransmission and enhances memory in both animals and humans (Foster 
et al., 2006; Tzavara et al., 2006).  Atomoxetine has also been shown to reduce the effects 
of nicotine withdrawal, confirming its involvement with acetylcholine (Davis and Gould, 
2007).  Several studies have shown drugs that positively modulate acetylcholine, also 
improve cognitive outcome following TBI (Dixon et al., 1997; for a review, see Warden et 
al., 2003).     
Clinical trials with atomoxetine in children and adults have shown that it is 
effective in maintaining control of ADHD, as well as preventing relapses of ADHD 
symptoms without increases in adverse effects (Christman et al., 2004).  Atomoxetine has 
also proved to be mildly successful in treating the symptoms of major depression, with 
clinical evidence of remission of depression after only 7 days of treatment (Kaplan et al., 
2007).  More recently, atomoxetine has demonstrated clinical effectiveness when used in 
combination with other selective serotonin reuptake inhibitors.  Finally, atomoxetine has 
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been investigated as a rehabilitative therapy for stroke patients, and a single oral dose of 
atomoxetine significantly improved performance in stroke patients using a paradigm that 
measures motor memory as a short-term model of use-dependent plasticity (Foster et al., 
2006).  
Atomoxetine has gathered considerable attention from the clinical TBI community 
for treating TBI- related attentional problems, hypoarousal, depression, and initiation 
disorders (Ripley et al., 2006).  However, no experimental or clinical studies have been 
undertaken to date, and the potential of atomoxetine remains undetermined. Based on 
previous studies, we posit that drugs that are positive modulators of the catecholamines 
will improve recovery of cognitive function following TBI.  This dissertation addresses 
dose response, therapeutic window and duration of treatment, all of which are important 
considerations in the treatment of TBI patients.  Therefore, the goal of this dissertation was 
to define an optimum therapeutic strategy for atomoxetine treatment following injury, and 
investigate a potential mechanism for the observed effects.  
 
Outcome Measures 
GAP-43 
Growth-associated- protein-43 (GAP-43) is a nervous-system specific, acidic 
membrane protein present in high levels in motile growth cones of elongating axons.  
GAP-43 has been implicated in a number of nervous system processes such as axon 
guidance, synaptic plasticity and neuroregeneration.  The rat protein contains 226 amino 
acids, and N-terminus membrane binding region, a calmodulin domain that is calcium 
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independent, and several phorphorylation sites, including protein kinase C (PKC) 
phosphorylation site serine 41 (Ser41) (Chapman et al., 1991; Benowitz and Routtenberg, 
1997).  GAP-43 is believed to play an important role in the guidance of axons to their 
correct targets and in modulating the formation of new connections between neurons 
(Benowitz and Routtenberg, 1997; Irwin and Madsen 1997), but GAP-43 is down-
regulated following synaptic rearrangement (Skene et al., 1986).  Depletion of GAP-43 
alters neurite outgrowth and growth cone morphology.  In contrast, overexpression 
promotes neurite sprouting, which is dependent on its PKC phosphorylation sites (Aigner 
et al., 1995).  The exact mechanism is unknown.  However, GAP-43 is implicated in 
regulating interactions between cytoskeletal components and the plasma membrane.  GAP-
43 is phosphorylated at serine 41 by protein kinase C-beta (PKC-β), which regulates 
calmodulin binding and activates GAP-43, and dephosphorylated by phosphates.  GAP-43 
expression in the nervous system has been well characterized both in developmental states 
and in the adult rat brain.  In the adult rat, GAP-43 expression is relatively high in the 
mature hippocampus and olfactory bulb, areas associated with continuing structural 
plasticity (de la Monte et al., 1989).  
Factors that Modulate GAP-43 Expression 
Numerous factors including growth factors, hormones and neurotransmitter 
agonists and antagonists have been shown to affect GAP-43 expression both in vitro and in 
vivo.  Fibroblast growth factor (FGF-2), epidermal growth factor (EGF), insulin growth 
like factor-1 (IGF-1 and -2), ciliary neurotrophic factor (CNFT) and nerve growth factor 
(NGF) have all been shown to increase both mRNA and protein expression of GAP-43 in 
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vitro (Costello et al., 1990; McNamara and Routtenberg, 1995; Piehl et al., 1998).  In vivo, 
brain-derived growth factor (BDNF), NGF, and FGF-2, increase the expression of GAP-43 
(Kobayashi et al., 1997; Fournier et al., 1997; Mearow, 1998; Schicho et al., 1999).  Drugs 
that affect neurotransmitter levels and neuronal activity have been shown to affect GAP-43 
also.  In vitro, following transaction of the Schaffer collateral pathway, activation of non-
NMDA receptors appears to be necessary for GAP-43 expression, reactive sprouting, and 
the recovery of neural transmission (McKinney et al., 1999).  Exposure to the NMDA 
antagonist MK-801 blocks induction of GAP-43 mRNA, suggesting some neuroprotective 
therapies used in trauma may prevent successful regenerative responses (Cantallops and 
Routtenberg, 1999).  Although atomoxetine itself has not been shown to influence GAP-
43, similar drugs that affect the NE transporter have been found to increase expression of 
GAP-43.  For example,  chronic treatment with the antidepressants desipramine, a NE and 
5HT reuptake inhibitor, or tranylcypromine, a monoamine oxidase inhibitor,  have found 
GAP- 43 mRNA and protein expression is increased (Chen et al., 2003; Laifenfeld et al., 
2005).  In situ hybridization, indicated that following desipramine treatment, GAP-43 
levels are specifically increased in the dentate gyrus (Chen et al., 2003), correlating with 
dense NE projections from the locus ceruleus to this region of the hippocampus.  
Dopamine (D1) agonists also increase GAP-43 expression (Williams et al., 2006).  
Neuronal GAP-43 expression has also been shown to be increased in vitro by 
administration of NE (Laifenfeld et al., 2002), concurrent with increases in two neurite-out 
growth promoting genes, neural cell adhesion molecule L1 and laminin. 
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Gap-43 Following Brain injury  
Numerous studies using a myriad of brain injury models have found alterations in 
GAP-43 expression are common following injury.  The first studies demonstrated 
increased GAP-43 following seizures in conjunction with mossy fiber sprouting (Meberg 
et al., 1993).  Kindling, which involves repeated electrical stimulation, also increases GAP-
43 expression.  Perforant path kindling leads to increased expression of GAP-43 in the 
CA1 stratum lacunosum moleculare (SLM) and the inner molecular layer (IML) of the DG 
(Dalby et al., 1995).  Numerous lesion studies have also demonstrated increases in GAP-
43.  Following lesions to CA3 pyramidal cells, GAP-43 is prominently found in new axon 
collaterals (McKinney et al., 1997).  Increased expression of GAP-43 is found in 
commissural fibers following fimbria/fornix and perforant path lesions (Patanow et al., 
1997), and transgenic mice overexpressing GAP-43 can induce partial regeneration of 
Purkinje cells following axotomy (Buffo et al., 1997).  GAP-43 is also expressed in 
response to deafferentation during reactive synaptogenesis (Schauwecker et al., 1995, 
2000).  Following entorhinal cortex lesions, significant increases in GAP-43 in the 
contralateral “sprouting” hippocampus are found (Lin et al., 1992).  The timing of these 
increases appears to be transient.  Reports suggest increases in GAP-43 occur between 2-
15 days following injury (Masliah et al., 1991; Benowitz et al., 1990).  These results 
suggest GAP-43 plays a role in the synaptic remodeling that occurs following lesions of 
the hippocampus. 
 Transient changes in GAP-43 expression have also been found following 
experimental spinal cord injury, ischemia, and traumatic brain injury models.  Increases in 
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GAP-43 were observed following compression injury in the adult rat spinal cord beginning 
around PID 4 and lasting until PID 9 (Li et al., 1996).  Transgenic mice over expressing 
GAP-43 produce long axonal projections (Bomze et al., 2001).  GAP-43 is elevated in the 
infarct penumbra at 4 days following cerebral ischemia and at 3 days in the boundary, 
suggesting the role of for GAP-43 in cortical sprouting (Furuya et al., 1997).  GAP-43 has 
also been reported in the hippocampus following global ischemia (Schmidt-Kastner et al., 
1997).  Interestingly, NMDA receptor blockade prevents the induction of GAP-43 
following ischemia, suggesting some level of neuronal activity is necessary for its 
expression (Luque et al., 2001).  Finally, GAP-43 expression is increased in the 
hippocampus and cortex following C-FPI of moderate severity (Hulsebosch et al., 1998).  
In cats, GAP-43 expression has been found up to 28 days in injured axons, suggesting a 
prolonged regenerative attempt (Christman et al., 1997).  Using L-FPI, increases in GAP-
43 expression were reported in the hippocampus at 48 h following injury but decreasesd 
from sham groups at later time points (Emery et al., 2000), suggesting there may be a 
limited time for enhancing or influencing post injury plasticity.  Although expression of 
GAP-43 is transiently increased after moderate injury in many models, a recent study 
documented no changes in GAP-43 expression in the hippocampus or cortex following 
severe-CCI (Thompson et al., 2006).  Therefore, it appears the ability for axonal and 
synaptic plasticity that occurs following moderate injury is diminished by more severe 
injuries.     
Several studies have investigated the effects of treatments on GAP-43 expression 
following different injuries. Increases in both GAP-43 and synaptophysin were found in 
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the ipsilateral and contralateral cerebral hemispheres of unilateral sensorimotor cortex 
injured rats following amphetamine treatment (Storemer et al., 1998).  Inhibition of Nogo-
A, a protein present in myelin which may prevent successful axonal regeneration following 
injury, prevented attenuated post-injury downregulation of hippocampal GAP-43 which 
correlated with cognitive improvement (Marklund et al., 2007).  GAP-43 axonal sprouting 
may be initiated by brain-derived neurotrophic factor-trkB signaling (BDNF will be 
discussed in more detail in a later section, Dinocourt et al., 2006).  Several studies suggest 
neurotrophic factors increase GAP-43 expression and this correlates with behavioral and 
functional improvements following injury (Dixon et al., 1997; McDermott et al., 1997; 
Fernandez et al., 1999).  Although the results differ depending on injury paradigms, as well 
as time course, the evidence of elevated GAP-43 expression during fiber outgrowth and 
synapse formation following CNS lesions and experimental TBI support the use of GAP-
43 as a marker for synaptic plasticity in the adult CNS (Benowitz and Routtenberg, 1997). 
Synaptophysin 
 Synaptophysin (SYN) is a 38 kDa glycoprotein found in the membrane of NT 
containing presynaptic vesicles and is involved in vesicular trafficking, docking and fusion 
of the synaptic plasma membrane (Wiedenmann and Franke, 1985; McMahon et al., 1996).  
SYN provides a molecular marker for axonal nerve terminals and synapses, but it is also 
used to estimate changes in synaptic number after cell loss or during neuronal remodeling 
and rearrangement (Masliah et al., 1990).   For example, SYN has been shown to be 
downregulated in cortical areas of aged animals and human Alzheimer’s patients, and the 
numbers correlated with disease progression (Ingelsson et al., 2004; Reddy et al., 2005).  
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The decrease in SYN in Alzheimer’s disease has been explained as a consequence of 
synaptic loss preceding neuronal death.   
Different experimental injury models have investigated changes in synaptophysin 
following brain injury.  Although a number of these studies have demonstrated changes in 
SYN expression, the time course has not been fully determined for each model and thus 
some questions still remain.  Following C-FPI, there was a slight reduction in SYN 
density, which may be attributed to cell death and the loss of synapses.  However, when 
FPI and entorhinal cortical lesion were combined there was a change in the distribution of 
SYN, suggesting synaptic reorganization, or reactive synaptogenesis (Prins et al., 2003). 
Following moderate CCI, synaptophysin levels were elevated in the ipsilateral 
hippocampus beginning at 24h after injury and lasting for 21 days, although the 7 day time 
point was elevated but not significant (Thompson et al., 2006).  Following L-FPI, 
increased innumostaining of SYN was found in the cortex and subcortical white matter as 
time progressed post-injury (Shojo and Kibayashi, 2006).  Although, most previous studies 
have explained increased immunoreactivity for synaptophysin in terms of synaptogenesis 
and neuronal regeneration, this study found increased synaptophysin in degenerated 
neuronal cell bodies and axons, suggesting that the increased SYP in the cortex following 
injury may represent inhibition of axonal transport and dysfunction of the synapse.  
Interestingly, there were no changes found in SYN levels at 2, 15 or 30 days after moderate 
fluid-percussion brain injury when western blot analysis was used (Shojo and Kibayashi, 
2006).  Clinically, Murdoch et al. (1998) reported a significant decrease in SYN levels, 
measured by western blot, in the cingulate gyrus of patients with head injury at 3h and 12.5 
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days after trauma.  Clearly there are obvious differences in injury models that are seen 
across a variety of outcome measures, however, these studies prove that both the model, 
and the time course for SYN induced changes must be considered when interpreting SYN 
levels.  Still, the results observed following TBI and other disorders support the use of 
SYN as a molecular marker for changes in synaptic number in this experiment.    
Brain-derived growth factor 
 Brain-derived growth factor (BDNF) belongs to the family of growth related 
neurotrophins that includes nerve growth factor (NGF), neurotrophin-3, and neurotrophin 
4/5. BDNF is the most abundant neurotrophic factor, and is found in high levels in the 
hippocampus and cerebral cortex (Phillips et al., 1990; Murer et al., 2001).  BDNF binds to 
two types of receptors, but shows the highest affinity for tropomyosin-related kinase B 
(TrkB, Kaplan and Miller, 2000).   BDNF has been implicated in playing an important role 
in the development of immature neurons, neural regeneration, synaptic transmission, 
synaptic plasticity, and neurogenesis (Patterson et al., 1996).  At the synapse, BDNF is 
important for both presynaptic and postsynaptic plasticity mechanisms, as well as long-
term potentiation (Pang et al., 2004; Messaoudi, 2005).  BDNF also plays a role in 
increasing presynaptic NT release and increasing synapse formation (Tyler and Pozzo-
Miller, 2001).  Enhanced expression of BDNF also improves cognition, and thus BDNF 
has been suggested to play a role in learning and memory (Messaoudi, 2005).  BDNF has 
been shown to mediate neuronal protection and enhancement of neurite outgrowth/axonal 
regeneration through its association with TrKB and its downstream effects on signaling 
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pathways (Cui et al., 2006).  Moreover BDNF has been shown to increase the expression 
of GAP-43 (Klocker et al., 2001)  
Alterations in BDNF expression have been hypothesized to play a role in 
depression and neurodegenerative diseases, and may have a role in the effects of 
antidepressant treatments.  Chronic antidepressant treatment has been shown to increase 
BDNF expression and induce hippocampal neurogenesis (Tardito et al., 2006; Sairanen et 
al., 2005).  Specifically, duloxetine (a 5-HT and NE reuptake inhibitor) has been shown to 
up-regulate BDNF mRNA and protein expression in the cortex, as well as affect the 
subcellular distribution of BDNF (Calabrese et al., 2007).  Other antidepressants that affect 
NE levels, such as desipramine and reboxetine, enhance BDNF expression and increase 
cell proliferation and neurogenesis in the dentate gyrus after chronic administration 
(Malberg et al., 2000; Czeh et al, 2001).  Several lines of evidence suggest that acute 
treatments (single-dose) fail to induce significant increases in BDNF, whereas more 
chronic treatments with antidepressants upregulate BDNF.  BDNF regulation changes have 
also been observed in the brains of Alzheimer’s (AD) patients.  Decreased concentrations 
of BDNF have been found in the hippocampus and temporal cortex of AD patients, which 
may interfere with neuronal integrity and plasticity (Ferrer et al., 1999; Connor et al., 
1997).    
Neurotrophins have been hypothesized to be an important neural substrate in TBI 
because of their roll in cell survival and neural plasticity (Gillespie et al., 2003).  Some 
studies have suggested that BDNF may be neuroprotective when given early, through a 
mechanism that involves caspase-3 (Kim and Zhao, 2005).  BDNF has also gained 
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attention for being a major modulator of MAG and Nogo-A inhibition.  In vitro studies 
demonstrate that neurons stimulated with BDNF have an enhanced ability to counteract the 
effects of inhibitory proteins through a mechanism involving the action of PKA (Gao et al., 
2003).  Thus, BDNF may be particularly beneficial in the post-TBI environment in 
overcoming the resistance to regeneration.  The recovery of neuronal cells and non-
neuronal cells may depend on the presense of growth factors and their receptors which act 
to support neuronal survival and sprouting of neuritis, and over come barriers to 
regeneration.  For these reasons, BDNF has been used as an outcome measure following 
injury and for investigating the effects of therapeutic treatments.  Several therapeutic 
agents, including exercise, vagus nerve stimulation and simvastatin, increase BDNF, which 
was correlated with increased functional outcome following TBI (Griesbach et al., 2004; 
Wu et al., 2008; Chytrova et al., 2008).   
Important to this experiment are the studies that show increased NE and DA 
neurotransmission can induce neuronal BDNF expression within the cortex and 
hippocampus (Fawcett et al., 1998; Ivy et al., 2003).  Therefore these neurottansmitters 
may be important signals in the brain for the mechanisms of neuronal survival, 
neuroplasticity, and neurogenesis (for a review, see Marien et al., 2004).  Catecholamine 
activity can also positively regulate astrocytic neurotrophic support.  IN vitro studies have 
shown that cultured cortical astrocytes, when exposed to DA, NE, or в-adrenergic agonists, 
exhibit marked increases in BDNF mRNA expression (Schwartz et al., 1994; Inoue et al., 
1997; Miklic et al., 2004; Juric et al., 2006).  Although the exact relationship between NE 
66 
and neurotrophins is unclear, the evidence taken together suggests there is a relationship 
between catecholamine levels and BDNF.   
 
Summary 
 Human TBI is a serious health and social concern both in the U.S. and globally.  
The vast majority of brain injuries are mild to moderate in severity, and often leave 
individuals with persistent cognitive and behavioral complaints.  Initial and persistent 
cognitive deficits, including problems with attention, information processing speed, and 
memory are among the most common complaints.  Therefore, it is extremely important to 
find therapeutic treatments that improve cognitive outcome following TBI. 
 Significant evidence suggests the catecholaminergic systems are altered following 
injury, and several studies have found improved outcome following treatments with 
positive modulators of the catecholamines.  Therefore, we posit that treatments that 
enhance catecholaminergic tone will positively influence structural and functional outcome 
following injury.  Atomoxetine is a selective NET inhibitor that is indicated for ADHD and 
symptoms of depression and anxiety.  The purpose of this study was to first examine the 
effects of atomoxetine on behavioral outcome in the MWM following a moderate level of 
experimental injury.  We will also address important issues that are clinically relevant 
including treatment dose, therapeutic window, and duration of treatment.  Finally, we will 
examine the expression of GAP-43, synaptophysin, and BDNF IR in the hippocampus to 
establish neuroplasticity correlates of the effects of atomoxetine following TBI.  Based on 
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the literature, there is evidence that NET inhibitors and dugs that positively modulate 
NE/DA may influence neurotrophins, and synaptic plasticity.     
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CHAPTER 2 METHODS 
 
 
Subjects   
Adult (3month-old) male Sprague-Dawley rats (Hilltop Lab Animals, Inc., 
Scottsdale, PA) weighing 300-360g were used in the study.  Animals were individually 
housed with free access to food and water in a 12-h dark-light cycle at 22° C.  All 
procedures followed the guidelines established in the Guide for the Care and Use of 
Laboratory Animals (U.S. Department of Health and Human Services) and were approved 
by the Institutional Animal Care and Use Committee. 
Drug Preparation 
Atomoxetine was provided by Eli Lilly and Co. (Indianapolis, IN).  Atomoxetine 
was dissolved in isotonic saline solution to achieve desired doses.  All drug injections were 
administered intraperitoneally (i.p) based on previous literature (Swanson et al., 2006). 
Experimental models of TBI: Rationale to use L-FPI 
 The understanding of TBI has been greatly enhanced by validating research in 
experimental models of injury.  Various models of experimental TBI are currently 
available, which are designed to replicate certain aspects of human brain injury.  Such 
models have used rodents, cats, rabbits, pigs and non-human primates to investigate the 
specific mechanisms leading to the various sequelae of brain injury (Dixon et al., 1987; 
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Gennarelli et al., 1982; Povlishock, et al., 1994).  No one animal model can replicate all 
aspects of human TBI, thus there are several preclinical models of TBI to properly 
characterize its underlying pathology.  Each of the models offers valuable information 
about certain aspects of the course of TBI.  A number of variables such as location of 
injury, the severity of trauma, and type of pathology are all taken into consideration when 
characterizing animal models.  For example, some of the models replicate the pathology of 
focal injury (e.g., cortical contusion injury), whereas other models focus more on diffuse 
injury (e.g., impact- acceleration, weight drop model by Marmarou et al., 1994).  Other 
injury models have combined the effects of TBI with secondary effects such as hypoxia, 
hypotension, ischemia, or entorhinal deafferntation (Cernak, 2005; Prins et al., 2003; Zhu 
et al., 2000).  In human TBI there is extensive overlap of focal and diffuse injury, 
therefore, experimental injury models that mimic both the focal and diffuse nature of TBI 
are particularly beneficial in studying the underlying mechanisms of brain injury.  It is 
important that these models can produce results that are reproducible and quantifiable, 
clinically relevant, and produce a continuum of injury severities.   
Fluid-percussion injury (FPI) is the most commonly used rodent model of TBI.  In 
this model injuries can be generated from either a central or lateral location.  Central fluid-
percussion injury delivers the fluid pulse along the central suture midway between bregma 
and lambda. Lateral fluid-percussion injury (L-FPI) delivers the injury to the parietal lobe 
midway between the coronal and lambdoid sutures.  L-FPI produces a combination of both 
focal and diffuse injury and has become one of the most extensively utilized models of 
injury (for review, Thompson et al., 2005).  The immediate physiological responses 
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include changes in blood pressure, brief respiratory arrest, decreased cerebral perfusion 
pressure, and reduced cerebral blood flow (Lighthall et al., 1989; Pfenninger et al., 1989).  
The predominant histological feature of L-FPI is a focal cortical contusion with 
accompanying intraparenchymal hemorrhage (McIntosh et al., 1989).  There is 
considerable neurodegeneration in and around the contused tissue that can last up to one 
year post-injury (Graham et al., 1997; Pierce et al., 1998).  Over the course of days to 
months, progressive degenerative cascades persist in additional brain regions such as the 
hippocampus (Cortez et al., 1989; Hicks et al., 1993), thalamus (Pierce et al., 1998; 
Rodriguez-Paez et al., 2005), striatum (Hallam et al., 2004; Hicks et al., 1996), and 
amygdala (Hallam et al., 2004; Colicos et al., 1996).  The injury generally affects the 
ipsilateral side, and few reports have demonstrated significant cell loss in either the brain 
stem or the contralateral side, which can be used as a qualitative comparison for some 
outcome measures (Pierce et al., 1998; Grady et al., 2003).  In addition, FPI show a direct 
relationship between the majority of pathological alterations and injury severity.  There are 
also dramatic subcellular and molecular responses that have been documented in L-FPI, 
such as changes in an array of cell-death, housekeeping, neurotrophic, cytokine, cell 
adhesion, and immediate early genes, as well as proteins involved in cell signaling, 
cytoskeleton, and synaptic transmission (Hayes et al., 1995; Hicks et al., 1997; Natale et 
al., 2003; O’Dell 2000).   Finally, FPI creates consistent and reproducible cognitive 
dysfunction using widely accepted behavioral paradigms (Hamm et al., 1993).  Cognitive 
deficits in memory have been observed between 48h and two weeks after FPI of moderate 
severity, which gradually improves towards sham levels over a year.  More severe injury 
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leads to enduring memory and behavioral dysfunction.  The clinical relevance, validity, 
and reproducibility of L-FPI support the use of this model to investigate both the pathology 
of TBI as well as the potential of pharmacological therapies to affect functional outcome.  
Therefore, L-FPI is well suited for the examination of our research questions.  To 
demonstrate the validity of our model, we have included cresyl violet photomicrographs 
from Sham, Injured, and Injured-Atomoxetine Treated groups (Figure 3). 
Surgical Preparation  
 All animals were anesthetized with 4% Isoflurane with 70% N2O: 30% O2 mixture 
for 4 minutes and placed in a stereotaxic frame.  The scalp was sagitally incised and a 4.8 
mm lateral craniotomy was trephined into the skull to the right of the sagittal suture 
midway between bregma and lambda.  A Leur-Loc syringe hub with a 2.6 mm diameter 
was secured on the skull at the site of the craniotomy with cyanoacrylate adhesive.  Two 
nickel-plated screws were placed 1mm rostra to bregma on the ipsilateral side and 1 mm 
caudal of the lambda on the contra lateral side.  Dental acrylic was applied around the hub. 
The scalp was then sutured and animals were allowed to recover.  
Fluid-Percussion Brain Injury  
 The fluid percussion device (Figure 2) used to produce experimental brain injury 
was identical to that used previously on rodents and was described in detail by Dixon et al., 
(1987).  Briefly, the device consists of a 60 cm long and 4.5 cm diameter Plexiglas 
cylinder with a rubber-covered O ring-fitted Plexiglas piston at one end.  The opposite end 
of the cylinder has a 2 cm long metal housing that contains a pressure transducer.  At the 
end of the metal housing is a 5mm tube with a 2.6-mm inside diameter which connects 
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with the surgically implanted Leur-Loc fitting implanted over the rat skull.  The device 
was filled with isotonic saline.  The injury was produced by a pendulum that strikes the 
piston of the injury device and injects a small volume of saline into the cranial cavity to 
produce a brief displacement and deformation of brain tissue.  The extra cranial pressure 
pulse was expressed in atmospheres (atm). 
 Twenty-four h after the surgical preparation animals were anesthetized with 4% 
isoflurane with 70% N2 O: 30% O2 mixture for 4 minutes.  Animals in the injured 
condition were then injured at 2.08 +/- .05 atm, equivalent to a moderate-level brain injury.  
Righting reflexes were recorded in all injured groups.  Rats assigned to sham-injury groups 
were anesthetized and connected to the injury device but received no injury.   
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Figure 2 A picture of the fluid-percussion device. 
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Figure 3 Histology Following Lateral-Fluid Percussion Injury.  The top panel(A-D):  
Representative cresyl-violot stained photomicrographs from A. Sham, B. Injured-
atomoxetine treated, and C-D. Injured-vehicle treated groups characterizing the L-FPI 
model.  The bottom Panel Left: Representative Photomicrographs of the CA3 region of the 
hippocampus from Sham-injured and Injured-Vehicle treated animals.  The bottom Panel 
Right: Magnification of the cortical contusion seen in both injured groups following L-FPI.     
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Behavioral Outcome Assessment 
 The impairments of cognitive function are the most significant and enduring 
consequences of human TBI.  The Morris Water Maze (MWM) is a standard well 
established method for the assessment of cognitive function of rats (Brandeis et al., 1989; 
Morris et al., 1982), and has become a standard test procedure in assessment following 
experimental TBI.  In the spatial reference memory task, animals learn to find a submerged 
escape platform occupying a fixed location in a large pool of water based on its location 
relative to extra-maze cues located in the testing room.  There are several advantages for 
using the MWM. The MWM is known to be sensitive to hippocampal damage and is a 
relatively simple procedure that rats learn rapidly and has been shown to be sensitive to 
FPI-induced cognitive dysfunction for at least 65 days (Lyeth et al., 1991; Miyazaki et al., 
1992).  Although other paradigms exist, many require food deprivation which may 
influence final outcome and confound results.  The MWM does not require food 
deprivation, and therefore is a superior model following injury.  It has also been shown that 
the deficits observed on this task are not confounded by visual, motor, or other non-
cognitive factors following injury (Hamm et al., 1993).  In all behavioral experiments 
(except where otherwise noted), rats will be examined on post-injury Days 11-15.  This 
time point coincides with large TBI-induced deficits, thus making drug effects more 
apparent. In addition, motor deficits produced following injury have abated.  This time 
point is a common time point for assessing spatial discrimination following injury, and 
thus the data is comparable to other pharmacological studies.  
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Apparatus: The maze is a large circular tank (180 cm diameter by 45 cm high) filled with 
water to a depth of 30 cm. (Figure 4).  The water temperature is maintained between 23°C 
and 26°C.  The hidden goal platform is placed 45cm from the outside wall in the southeast 
quadrant and remains constant throughout testing.  The pool is located in a room with 
numerous extra maze cues that remain constant throughout testing.  
Procedure: Rats were given 4 trials per day for 5 consecutive days.  On each day, rats were 
placed in a pool by hand in one of four locations (north, south, east, west) facing the wall. 
Each animal started a trial at each of the four locations on each day.  The order of starting 
locations was randomized each day to minimize practice effects.  The goal platform was 
placed 45cm from the outside wall in the southeast quadrant and remained constant 
throughout testing.  Rats were given a maximum of 120 sec to find the goal.  After this 
time, the rats were placed on the goal and held there for 30 sec.  The rats were then 
removed from the maze and placed in an incubator until the next trial.  Latency to reach the 
goal was recorded using a video tracking system (Videomex Columbus Instruments, Ohio). 
This device also recorded path length to the platform, which allowed for the calculation of 
swim speed.  Latency to find the platform was the primary variable analyzed.  Swim speed 
was also calculated to ensure there were no motor deficits or drug effects interfering with 
results.  
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Figure 4 A cartoon of the Morris Water Maze 
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CHAPTER 3 
EXPERIMENTAL RATIONALE, DESIGN, & RESULTS 
 
Experiment 1: Optimum Dose Determination 
Rationale 
 Pharmocological strategies aimed at increasing neural activity in the chonic stages 
of TBI have demonstrated some success in increasing cognitive performance in the MWM 
following injury (Whiting and Hamm, 2005).  Particularly, drugs that modulate NE and 
DA have been successful at enhancing specific aspects of cognitive dysfunction in human 
TBI.  Atomoxetine is a nonstimulant selective NET inhibitor that increases extracellular 
levels of NE and DA.  No previous studies have investigated the effects of atomoxetine on 
cognitive recovery following experimental TBI.  Therefore, this experiment examined 
which dose of atomoxetine would be the most effective at reducing cognitive deficits 
associated with the consequences of brain injury.  The lower doses (.03-1 mg/kg) were 
chosen based on the therapeutic concentration range of atomoxetine in humans and 
previous literature in rodents (Bymaster et al., 2000).  The higher doses (3-9 mg/kg) were 
used to fully investigate the effects of different doses in TBI.  Although, these doses may 
not be clinically relevant in ADHD patients, no investigations have examined atomoxetine 
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treatment following TBI.  Therefore, this study used a full range of doses to demonstrate 
the effects of atomoxetine on cognitive recovery following TBI. 
Design 
The experiment was designed to find the most effective dose of atomoxetine for 
reducing post-injury cognitive deficits.  All animals were randomly assigned to one of 
seven treatment groups: injured + .3 mg/kg atomoxetine (n=10), injured + 1 mg/kg 
atomoxetine (n=10), injured + 3 mg/kg atomoxetine (n=10), injured + 9 mg/kg 
atomoxetine (n=10), injured + vehicle (n=10), sham-injured + 1 mg/kg atomoxetine (n=10) 
and sham injured + vehicle (n=10).  Each individual injection was administered at 3 
mg/kg, 1mg/kg, 3mg/kg, or 9mg/kg dose, i.p., and animals in the injury + vehicle groups 
received an equal volume of saline (1 ml/kg).  Vehicle or atomoxetine treatment was 
administered to animals beginning 24h after injury and continued once daily for 15 days.  
All animals were injected with either vehicle or atomoxetine at the same time each day. 
 Morris water maze performance was determined on PIDs 11-15.  On MWM testing days, 
administration of drug or vehicle occurred 1 hour before initiation of testing.   
 Results  
No significant difference in recovery of righting reflex time was found between any 
injured group, demonstrating injury severity was consistent between all injured groups (F 
(4,39)  = 1.001, p=.419, data not shown).  Analysis of spatial learning acquisition by a 
split-plot [6 (Group) X 5 (Day)] analysis of variance (ANOVA) revealed a significant main 
effect on Group (F (5,54) =14.465, p < 0.001), demonstrating a decreased latency to find 
the goal (Figure 5).  Post-hoc comparisons with Tukey’s Honestly Significant Differences 
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(HSD) test indicate that injured animals treated with .3 mg/kg, 1mg/kg, and 3 mg/kg 
atomoxetine differed significantly from injured animals treated with vehicle, demonstrated 
by the significant improvement in MWM performance (P< 0.001).  In fact, injured animals 
receiving the .3 and 1 mg/kg atomoxetine treatment did not differ significantly from sham 
animals (P>.05).  There were no significant differences between sham injured animals 
receiving either vehicle or 1 mg/kg atomoxetine, indicating that drug administration did 
not affect performance on the MWM in sham animals (Figure 6, F (1,18) = 1.615, P > .05).  
Analysis of swim speed found no significant group differences, suggesting there were no 
motor, or motivational factors caused by injury or drug effects (Figure 7, F (6, 62) = 1.466, 
P = .205). 
 Discussion 
This is the first study to investigate the efficacy of atomoxetine in treating post-TBI 
cognitive impairments.  The results demonstrate that daily chronic, post-injury treatment 
with low doses (.3, 1, 3 mg/kg) of atomoxetine reduces cognitive impairments following 
L-FPI in rats when initiated 24 h after injury.  Treatment at the higher dose (9mg/kg) did 
not offer any benefit.  The dose-dependant response suggests only low doses of 
atomoxetine are effective in attenuating cognitive deficits.  Animals treated with 9 mg/kg 
atomoxetine appeared to be unusually aggressive and easily agitated (qualitative 
observation), which may have affected their performance in the MWM.  However, no 
significant differences in swim speeds were observed between any of the groups, 
suggesting the drug did not affect their performance through an effect unrelated to injury.  
Atomoxetine has gathered much interest from the clinical TBI community for treating 
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post-injury cognitive deficits (Ripley 2006), but this is the first study to demonstrate that 
atomoxetine aids in cognitive recovery following experimental injury in animals.  The 
results of the current study are similar to previous results using stimulant treatments such 
as methylphenidate (Kline et al., 2000; Napolitano et al., 2005); however, atomoxetine 
offers advantages over traditional stimulants, in that atomoxetine is not a controlled 
substance, has little abuse potential, and offers once-daily dosing (Christman et al., 2004).  
Therefore atomoxetine may be a more practical treatment for cognitive-related deficits in 
TBI patients.   
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Figure 5 MWM results for Experiment 1. The goal latencies for injured animals treated 
with .3, 1, and 3 mg/kg atomoxetine were significantly different than injured animals 
treated with vehicle alone (p<.05).  The results also indicated latencies in the sham-vehicle 
group were not significantly different from injured animals treated with .3, and 1 mg/kg 
atomoxetine.  
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Figure 6 MWM results for Sham Groups.  The mean (±SEM) latency (seconds) to 
locate a hidden platform in the Morris water maze on days 11-15 post-injury.  Comparison 
of sham-vehicle treated and sham-1 mg/kg atomoxetine treated revealed no significant 
differences suggesting administration of atomoxetine did not affect MWM performance 
through mechanisms unrelated to injury.   
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Figure 7 Swim Speeds for Experiment 1.  The mean swim speeds (cm/sec) for each 
group are shown.  A one-way ANOVA found no significant differences between the 
groups, indicating the results of Experiment 1 are not due to injury or drug effects on swim 
speed.     
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Experiment 2:  Examination of Therapeutic Window 
Rationale 
  The aim of this experiment was to investigate the temporal therapeutic window 
for post-injury pharmacological treatment of cognitive impairments with atomoxetine.  
Delaying the initiation of chronic administration is clinically important because many of 
the cognitive deficits observed following TBI may not be apparent or may be masked by 
other disorders immediately after the injury.  In addition, there are a number of people 
living with TBI-related disabilities that may benefit from treatments at delayed time points.  
Post-traumatic neural depression appears to be temporally bound to behavioral change, 
with both being impaired after injury and changing in parallel over time.  Following injury, 
there may be a critical period for treatment to provide benefits in cognitive outcome.  It is 
well known that a number of secondary injury cascades occur for hours to weeks following 
injury.  Although, the exact time course for these injury induced changes varies according 
to model and outcome measure, it is hypothesized that drugs with neuroprotective 
mechanisms may have limited therapeutic windows, and therefore treatments initiated at 
later time points after injury may be ineffective due to irreversible damage.  In addition to 
secondary injury mechanisms, there are also mechanisms of neural recovery, and the 
endogenous neural plasticity response begins to mount within the first week following 
injury.  Therefore, drugs that enhance this endogenous plasticity response may be required 
to be initiated early after injury.  In contrast, if drugs initiated at delayed time points (over 
1 week) post-injury still provide cognitive benefit, it would suggest a different mechanism 
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of action.  Therefore, this study also provides information to help clarify the potential 
mechanism.          
Design    
Animals were randomly separated into one of three groups: injured + saline 
treatment (n=10), injured + 1 mg/kg atomoxetine treatment (n=9), and sham-injured + 
vehicle (n=8).  Following injury, animals did not receive any treatment on days 1 through 
10 after the trauma.  Beginning on post-injury day (PID) 11, animals were treated with 
atomoxetine or saline once daily at the same time for the remainder of the experiment.  
Cognitive performance was assessed in the MWM after 15 days of drug treatment on PID 
26-30.  On MWM testing days, administration of drug or vehicle occurred 1h before 
initiation of behavioral testing.   
Results  
A split-plot ANOVA [3 (Group) X 5 Day] indicated there was a significant effect 
of Group on Goal Latency ( F(2,24) =7.542, P<.05); however, post-hoc comparisons using 
Tukey’s HSD test indicate that injured animals treated with 1 mg/kg atomoxetine were not 
significantly different from injured animals treated with vehicle (Figure 8, P > .05).  There 
were no significant differences in mean righting times (F (1,17)  = 2.084, P=.174) or swim 
speeds (F (2,24)  = 1.866, P=.177) between groups (data not shown).   
Discussion 
 The time course of TBI-induced changes and the timing of treatment are extremely 
important considerations when evaluating pharmacological interventions.  This study was 
especially important as it looked at the therapeutic window over a very long period of time 
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post-injury.  Clinically, this paradigm is important as it offers crucial information that 
could be used in patients where cognitive problems may not be apparent immediately 
following trauma.  From an experimental point of view, this experiment offers important 
information about a potential mechanism for atomoxetine’s observed effects.  The results 
of this experiment suggest treatment early after injury is the critical time period for 
enhancing behavioral outcome with atomoxetine.  Although few experimental studies have 
addressed therapeutic window along with dose response when investigating preclinical 
TBI pharmacotherapies, two previous studies in our lab found that beneficial treatments 
that were initiated at 24 h after injury were no longer effective if treatment initiation was 
delayed for 11 days post-injury (O'Dell et al., 1995; Pike et al., 1995).  In fact, only one 
study, using aniracetam, found that chronic drug treatment initiated at 24 h and at 11 days 
post-injury were equally effective at reducing trauma-induced MWM deficits (Baranova et 
al., 2006).  Clinically, this study suggests atomoxetine may have a limited therapeutic 
window for influencing post-injury cognition; however, controlled clinical trials are 
needed to fully examine when atomoxetine may be most effective in humans.        
From a mechanistic perspective, the results offer valuable information regarding 
atomoxetine’s mechanism for influencing cognition following experimental TBI.  Previous 
studies, in several models have suggested that NE neural transmission begins to decrease 
as early as 6h post-injury and may remain depressed for as long as 8 weeks post-injury 
(Dunn-Meynell et al., 1998).  A dramatic loss of cells in the LC has also been observed in 
the chronic stages following injury (Fujinaka et al., 2003).  Likewise, several studies have 
found DA metabolism is decreased for several weeks following injury (McIntosh et al., 
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1994; Massucci et al., 2004).  Therefore, one hypothesis may be that atomoxetine, by 
increasing extracellualar levels of NE and DA, corrects chronic primary deficiencies in 
these neurotransmitters.  In addition, because the neuromodulatory neurotransmitters are 
functionally interrelated, a derangement in one system can sometimes be felt 
“downstream” in another, e.g. influencing neuronal firing rates or the sensitivity of 
receptors.  Therefore, increasing NE and DA may also correct chronic secondary 
deficiencies in other neurotransmitter systems.  However, the results of this experiment 
suggest atomoxetine is not simply correcting NT deficiencies that exist in the chronic 
stages of injury.  Initiating atomoxetine 10 days post- injury completely eliminated the 
beneficial effects observed in experiment 1.  This suggests atomoxeteine’s effects on 
cognition are related to TBI mechanisms occurring early after injury.  Although animals do 
improve cognitively over time, there is still a significant difference between the injured-
vehicle treated and sham-injured groups when MWM training is performed on PID 26-30.  
If atomoxetine treatment was simply correcting NT deficiencies that existed in the chronic 
stage, one prediction may be that treatment initiation at a delayed time point (10 days) 
would still be able to improve cognitive performance in the MWM.  Therefore, it is 
unlikely that atomoxetine simply mediates the effects of a neurotransmitter-based 
diaschisis (RFD) in the chronic phase of injury, atleast in this model of TBI.   
A more likely conclusion may be that increased extracellular catecholamines 
influence the events occurring in the first week following injury.  This is a time period 
when a number of secondary injury mechanisms, as well as neural recovery mechanisms 
may influence functional outcome.  The literature on NE suggests this neurotransmitter 
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may be neuroprotective and influence neural plasticity under certain circumstances via 
various mechanisms.  In addition, neuronal depression occurring during this time period 
may affect many aspects of brain plasticity and neural recovery.  Resolution of neural 
depression may depend on creating an optimal catecholaminergic environment.  Future 
studies will be designed to explore this hypothesis.       
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Figure 8 MWM Results Following Delayed Atomoxetine Treatment.  The mean 
(±SEM) latency (seconds) to locate a hidden platform in the MWM on post injury days 26-
30 is shown. Injured animals treated with 1 mg/kg atomoxetine were not significantly 
different from injured animals treated with vehicle. 
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Experiment 3:  Termination of Chronic Administration before MWM 
 Rational 
  The aim of this study was to examine whether the continued administration of 
atomoxetine is necessary for the enhancement of performance on the spatial memory test 
in the MWM following TBI.  This study determined if chronic atomoxetine treatment early 
after injury would lead to long-term enhancement of cognition, or if continued atomoxetine 
treatment was necessary to observe improvement.  The experiment was designed to 
determine whether atomoxetine must be active in the organism during the time of MWM 
testing in order to provide cognitive enhancement, or if treatment during periods of 
postinjury-induced plasticity were sufficient to produce beneficial results.     
Design 
Animals were randomly separated into one of three groups: injured + saline 
treatment (n= 9), injured + 1 mg/kg atomoxetine treatment (n=10), and sham-injured + 
vehicle (n=11).  Administration of the drug or vehicle began 24 h after injury, and 
continued daily for 7 days.  Atomoxetine treatment was then terminated, and a drug wash 
out period was allowed before behavioral testing.  Spatial memory performance in the 
MWM was assessed on post-injury days 11-15, and no drug treatment was given on testing 
days.      
Results  
A split-plot ANOVA [3 (Group) X 5 Day] indicated there was a significant effect 
of Group on Goal Latency (Figure 9, F (2, 27) =47.421, P<. 001).  Post-hoc comparisons 
using Tukey’s HSD test indicated that both sham-vehicle treated animals and injured 
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animals treated with 1 mg/kg atomoxetine were significantly different than injured animals 
treated with vehicle alone (P < .001).  In fact, the injured group treated with atomoxetine 
had latencies that were not significantly different from sham-vehicle treated animals.      
There were no significant differences in mean righting times (P=.186) or swim speeds 
(P=.095) between groups.  
Discussion   
The present study has demonstrated that cognitive dysfunction associated with L-
FPI can be significantly attenuated with daily (7 day) administration of atomoxetine 
initiated at 24h after injury.  Atomoxetine treatment was terminated prior to cognitive 
assessment and a wash-out period was allowed before MWM testing was performed.  The 
injured-atomoxetine treated group exhibited significant cognitive improvement compared 
to the injured- vehicle treated group, suggesting chronic atomoxetine treatment in the early 
phase after injury may lead to long-term adaptive changes.  The results also suggest that 
continued atomoxetine treatment during MWM testing is unnecessary to observe beneficial 
effects in cognitive performance.      
Taken together with the previous experiments, the results strengthen the conclusion 
that atomoxetine’s mechanism of action is related to the early phase following injury.  
Previous experiments, employing a 7 day drug-treatment paradigm following TBI, found 
drugs that enhance NE and DA, such as the MAO-inhibitor L-Deprenyl and the D1 agonist 
SK-38393, also enhance cognition in the MWM (Zhu et al., 2000).  The behavioral effects 
were correlated with enhanced synaptic plasticity, and it has been suggested that these 
drugs may be able to affect neural remodeling.  This is inline with previous studies of NE 
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and DA that suggest these NTs can affect plastic events, including intracellular signaling, 
changes in synaptic transmission, modification of neuronal architecture, and/or 
neurogenesis (Manji et al., 2003; and Millan, 2004).  Therefore, one hypothesis that 
develops from this study is that chronic atomoxetine treatment during periods of neural 
plasticity following TBI may contribute to long-term adaptive structural reorganization.  .    
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Figure 9 Results of Terminating Chronic Atomoxetine Treatment before MWM 
Testing.  The mean (±SEM) latency (seconds) to locate a hidden platform in the MWM on 
post injury days 11-15 is shown.  Injured animals treated with 1 mg/kg atomoxetine were 
significantly different from injured animals treated with vehicle. 
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Experiment 4:  Administration of a Single Dose of Atomoxetine 
Rationale 
 This experiment was designed to determine if a single dose of atomoxetine was 
sufficient to observe enhanced cognition or if once daily chronic (7 day) treatment was 
necessary to observe improved spatial learning.  The experiment was also designed to help 
clarify a potential mechanism for the observed effects of atomoxetine following 
experimental TBI.  Drugs that act through inhibition of catecholamine transporters have 
been shown to immediately increase levels of these NTs (Mattiuz et al., 2003); however, 
there tends to be a delay or a required period of chronic treatment before any observed 
behavioral changes are exhibited in various disorders such as depression and ADHD.  The 
temporal mismatch between the rapid elevations in extracellular monoamine levels induced 
by selective norepinephrine reuptake inhibitors and their slow onset of action (weeks) in 
clinical use may reflect the initiation of plastic events including: alterations in receptor 
density, intracellular signaling changes in synaptic transmission, modification of neuronal 
architecture and/or neurogenesis (Manji et al., 2003; Millan, 2004).  Likewise, following 
TBI, these drugs may act in a similar fashion and therefore require chronic administration 
to be effective.  
  In contrast, many studies have found that pretreatment or post-treatment with a 
single dose of catecholaminergic drugs following injury affords protection and enhances 
neurological outcome.  For example, studies with amphetamine have found that a single 
oral dose following injury, combined with physical training, can have beneficial and 
lasting effects on motor outcome (Bash-y-Rita and Bjelke, 1991; Queen et al., 1997).  
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Likewise, a single dose of atomoxetine has been shown to improve outcome in stroke 
patients (Foster et al., 2006).  Clinically, a single-dose of methylphenidate administered 
early after injury has been shown to increase cognitive performance in various tasks of 
attention, memory, and speed of processing in TBI patients (Kim et al., 2006).  Improved 
cognition following a single dose of treatment at 24h may suggest the mechanism is more 
related to one or several of the secondary injury cascades observed following TBI.  Still, it 
can not be ruled out that a single dose of these drugs may act though other mechanisms.  
Therefore, this study was not intended to provide conclusive evidence about the 
mechanism of atomoxetine, but rather to help clarify how this drug works following TBI 
and to determine a course of future outcome measures that may be related to the 
mechanism.  
Design 
 Animals were randomly separated into one of three groups:  injured + saline 
treatment (n=10), injured + 1 mg/kg atomoxetine treatment (n=9), and sham-injured 
(n=10).  Animals in the injured groups received a L-FPI of moderate severity, and animals 
in the sham group underwent surgical preparation for received no injury.  Twenty-four h 
after injury, animals received a single injection of either atomoxetine (1 mg/kg), or an 
equal volume of saline.  Animals were returned to their cages and handled and weighed 
daily for the remainder of the experiment.  No further treatments were given after PID 1.  
Spatial memory performance in the MWM was assessed on post-injury days 11-15. 
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Results 
  A split-plot ANOVA [3 (Group) X 5 Day] indicated there was a significant effect 
of Group on Goal Latency (Figure 10, F (2, 26) =37.799, P<.001).  However, post-hoc 
comparisons using Tukey’s HSD test indicated there were no significant differences 
between the injured-vehicle and injured-atomoxetine treated groups (P=.110).  A one-way 
ANOVA was performed to observe group differences for each day.  Although, no 
differences were observed between the two injured groups on days 1-3 of MWM testing, 
there was a mild effect on latency in the atomoxetine treated group on day 4 and 5.  There 
were no significant differences in mean righting times (P=.715) or swim speeds (P=.118) 
between groups (data not shown).  
Discussion 
The results found no significant differences between the two injured groups when a 
single-dose of atomoxetine was given 24 h after injury.  There does appear to be a mild 
effect in the injured-atomoxetine treated group on the final two days of MWM training, 
although it was not significant over all five days of testing.  Previous studies have shown 
blockade of α-adrenoreceotors prior to brain injury impairs recovery (Dunn-Meynell et al., 
1997), whereas intraventricular NE infusion prior to injury improves recovery (Boyeson et 
al., 1990).  In addition, several studies in humans and animals have demonstrated that a 
single dose of d-amphetamine or atomoxetine following stroke enhances functional motor 
outcome (Sawaki et al., 2002; Foster et al., 2006).  In this study, a single dose of 
atomoxetine at 24h after injury was unable to augment cognitive outcome significantly.  It 
is unknown what effects atomoxetine may have if initiated at earlier, more acute time 
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points, in which NE may be neuroprotective against one or many of the secondary injury 
cascades occurring following injury.  Although single treatments with NET inhibitors are 
known to increase the extracellular levels of NE through transporter blockade, it appears 
effective therapy in certain disorders requires chronic administration of these drugs.  This 
suggests long-term adaptive changes in neuronal function are necessary for their 
therapeutic effects.  Similarly, in this experiment, a single treatment with atomoxetine 
following TBI did not produce the same benefit in cognition as chronic treatment (7days).  
Although, the mechanism underlying this therapeutic effect is not understood, several 
studies have demonstrated chronic, but not acute treatments, with catecholamine-
enhancing drugs are able to up-regulate the cAMP signal transduction system, increase 
neurotrophins and other factors involved in cell survival and growth and promote 
neurogenesis (Thome et al., 2000; Chen et al., 2003; Calabrese et al., 2007).  Therefore, a 
single treatment may not be sufficient to elicit significant adaptive structural changes that 
could influence cognitive outcome.  Future studies will explore this possibility.  
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Figure 10 MWM Results Following Administration of a Single Dose of Atomoxetine 
24h after L- FPI.  The mean (±SEM) latency (seconds) to locate a hidden platform in the 
MWM on post injury days 11-15 is shown.  Post-hoc comparisons found no overall 
significant differences between the two injured groups; however, there is a trend on day 4 
and day 5 of MWM training towards improved latency in the atomoxetine-treated group.    
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Experiment 5:  Effects of Atomoxetine on Protein Expression of Plasticity 
Markers 
Rationale    
The behavioral studies found low doses of atomoxetine are effective at attenuating 
cognitive deficits when initiated early and given daily (7 days) after injury.  In fact, 
improved cognitive performance was even observed after chronic atomoxetine treatment 
was terminated, suggesting the potential for this drug to have long-term effects.  This study 
was designed to investigate changes in plasticity markers by correlating the observed 
behavioral responses following atomoxetine treatment with changes in structural plasticity 
markers.  Several studies suggest the catecholamines and catecholamine-enhancing drugs 
may influence neuroplasticity.  Therefore, we decided to investigate changes in the 
expression of GAP-43, synaptophysin, and BDNF following post-injury atomoxetine 
treatment.  We chose these markers because they have been previously characterized in 
TBI models and are sensitive to injury induced changes during the period of drug 
treatment.  GAP-43 has been implicated in axon guidance, synaptic plasticity, and 
neuroregeneration, and its expression serves as a marker of these processes following 
injury.  Synaptophysin is a marker for the total number of synapses, which may reflect 
both the loss of synapses as well as synaptic reorganization.  Finally, BDNF is a 
neurotrophin that is sensitive to both TBI and NE-enhancing drugs.  Therefore, we posit 
that atomoxetine treatment will enhance the expression of these markers, which may 
represent adaptive changes that are correlated with the observed behavioral responses.  
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Design 
Animals were randomly separated into one of three groups: injured + saline 
treatment (n=5), injured + 1 mg/kg atomoxetine treatment (n=5), and sham injured (n=5).  
Animals were injured and sham injured as described previously.  Beginning 24h after 
injury, animals received either saline or 1 mg/kg atomoxetine depending on group 
assignment.  Treatment continued for 7 days, in which animals were sacrificed and brain 
tissue collected for Western blot analysis.  Contralateral hippocampi were removed from 4 
brains for each group (n=4).       
Tissue Preparation & Western Blot Analysis: At 7 days post-injury, animals were 
deeply anesthetized with 4% isofluorane and decapitated.  After removing the full brain, 
ipsilateral and contralateral hippocampus sections were dissected and separated on ice-cold 
glass plates and immediately transferred to a centerfuge tube containing 150µl of Ripa 
lysis buffer (1X Ripa, Upstate; 1 tablet Complete Protease Inhibitor, Roche).  Samples 
were homogenized and then centrifuged at 14,000g for 20 minutes at 4°C.  Total protein 
concentrations were determined using a Bio-Rad microassay, and a standard regression 
equation was used to calculate protein quantity from spectrophotometer readings.  Samples 
were diluted 1:20 before water was added in appropriate concentrations to ensure equal 
quantities of protein loaded in each lane.  7.5µl of sample buffer and 1.5µl of reducing 
agent were added to each tube, before heating the samples for 5 minutes at 95°C.  Samples 
were then loaded on to a SDS–PAGE precast gels (4-12% Bis-Tris Criterion XT, Bio-
Rad), and run, using 1X MES Running Buffer or 1X Mops Running Buffer (Bio-Rad) at 
150V for 1h.  The separated gels were then transferred to PVDF membranes (Bio-Rad, 
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100V, 1H) using Transfer Buffer (1x Tris/Glycine Buffer (Bio-Rad) + MeOH).  Following 
transfer, the gels were removed and stained with Coumassie Blue to ensure complete 
transfer to the membranes.  The membranes were blocked in .5% non-fat dry milk +.05% 
Tween 20 in phosphate-buffered saline for 1 hour at room temperature on a shaker.  The 
membranes were then incubated overnight at 4°C in TBS-T(.05%Tween 20) and the 
appropriate dilution of primary antibody.  The following monoclonal antibodies and 
dilutions were used: GAP-43 (1:1000, 7B10, Invitrogen), synaptophysin (1:300, SVP-38, 
Sigma), BDNF (1:300, sc-546, Santa Cruz Biotechnology, Inc.).  The membranes were 
washed six times in TBS-T (.05%) and incubated for 1 hour with a goat anti-mouse 
secondary antibody conjugated to horseradish peroxidase (1:20,000, Rockland, Lot # 
18329).  Membranes were thoroughly washed before being developed for 5 minutes with 
SuperSignal (Pierce).  The blots were then imaged and quantified using GeneSnap and 
GeneTools software (Syngene).  Negative controls included lanes that received the same 
treatments except the primary antibody was omitted.   
The membranes were re-probed using monoclonal β-Actin (1:3000, Sigma) as a 
loading control.  Each membrane was washed in methanol for 5-10 minutes, followed by 2 
washes (5minutes) in DI water.  The membranes were then placed in 1X Western Re-Probe 
Solution (G-Biosciences) for 1 hour on a shaker, and then washed 3 times (5 min each) in 
PBS-with .1% Tween-20.  The membranes were then blocked in .5% non-fat dry milk + 
PBS-with .05% Tween-20 for 1 hour, and then incubated overnight on a shaker with 
primary antibody + PBS-T with milk.  The membranes were washed 3 times in PBS-T + 
milk and 3 times with PBS before being incubated for 1 hour in goat anti-mouse secondary 
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antibody (1:20,000, Rockland).  Membranes were washed, developed, and analyzed as 
previously described.      
Results 
 GAP-43 is expressed at elevated levels in growth cones during axonal extension 
and is believed to be one component of injury-induced plasticity.  Immunoblot analysis 
was performed to confirm changes in GAP-43 expression following injury and to quantify 
any changes in the amount of GAP-43 following 7 day post-injury treatment with 
atomoxetine.  The GAP-43 antibody (7B10) appeared at approximately 46 kDA and 
produced 1 consistent band across all lanes (Fig. 11A).  The omission of primary antibody 
was used as a negative control to ensure specific binding of the antibody.  The negative 
control consistently produced no staining in multiple blots (Fig. 11B).  Beta-Actin (AC-15, 
42 kDA) was used as a control to ensure equal loading of protein between lanes (Fig. 11C).  
A one-way ANOVA found no significant differences in the expression of Beta-Actin 
between the groups (F (2,12)=2.224 P=.151).  Statistical analysis using a one-way 
ANOVA indicated there was a significant group effect on GAP-43 expression in the 
ipsilateral hippocampus (Fig. 11D, F (2,12)=7.189, P< .01).  Post-hoc analysis using the 
LSD test indicated there was a small but significant decrease in GAP-43 expression in the 
ipsilateral hippocampus of injured animals compared to sham levels (P=.034).  The injured 
group treated with atomoxetine showed significantly increased GAP-43 levels when 
compared to injured-vehicle alone (P=.003).  In fact, there were no differences in GAP-43 
expression between the Injured- Atomoxetine-Treated and Sham-groups (P=.204), 
indicating the injury-induced decreases in GAP-43 seen at Day 7 post-injury can be 
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counteracted by treatment with atomoxetine  post-injury.  The contralateral hippocampus 
was also dissected and used for Western Blot analysis (Figure 12).  A one-way ANOVA 
found no significant differences in GAP-43 expression in the contralateral hippocampus 
between any of the groups (F (2, 9) =1.482, P=.278).                    
 Synaptophysin (38kDA) has been used previously to quantify changes in synapses 
following injury and during synaptic reorganization.  Immunoblot analysis was performed 
on synaptophysin to observe any injury-induced changes at PID 7 following L-FPI.  The 
experiment was designed to compare differences in injury-vehicle treated and injury-
atomoxetine treated animals.  A one way ANOVA found no statistical differences between 
the groups (P= .501), indicating that the amount of protein expression was not significantly 
different between injured-vehicle and sham groups and between the two injured groups 
(Figure 13).  
The expression of BDNF (14kDa) protein in the ipsilateral and contralateral 
hippocampus was analyzed using a one-way ANOVA (Figure 14).  Although, no 
significant differences were detected between the ipsilateral groups (P= .065), post-hoc 
analysis using the Least Significant Differences (LSD) test found a significant increase in 
the expression of BDNF in the ipsilateral hippocampus of injured- atomoxetine treated 
animals over injured-vehicle treated animals (P= .027), suggesting atomoxetine treatment 
may influence neurotrophins when given chronically after injury(Fig. 14a).  Analysis of 
the contralateral hippocampus (Fig. 14b) found a significant effect on group (F 
(2,10)=5.455,P=.025).  Post-hoc comparisons using LSD found there was a significant 
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increase in BDNF expression in atomoxetine treated animals over sham-injured animals 
(P=.020).     
Discussion 
In this experiment we measured the levels of GAP-43 and synaptophysin, which 
are normally found in growth cones and synaptic vesicles, to obtain an estimate of the 
effects of L-FPI on these markers and to show how atomoxetine treatment may influence 
plasticity.  We also looked at changes in BDNF, a neurotrophin that may play an important 
role in post-injury plasticity.  Time-dependant changes in GAP-43 and synaptophysin 
expression appear to be a common event following brain injury (Christman et al., 1997; 
Emery et al., 2000).  Because GAP-43 has been implicated in many processes including 
neuronal growth, the formation of novel neuronal connections, synaptic remodeling, and 
neuronal sprouting following insult, it has been widely used as a marker of axonal and 
synaptic plasticity.  Although TBI is generally followed by a period of increased axonal 
sprouting, characterized by increased GAP-43 and synaptophysin staining, the regenerative 
response has been shown to be short-lived and varies depending on the injury model and 
severity (Thompon et al., 2006).  A previous study using L-FPI found GAP-43 
immunoreactivity was elevated bilaterally at 24 h and 48h after injury; however, on PID 7 
the levels of GAP-43 had returned to sham levels, or had even decreased below sham 
levels (Emery et al., 2000; Marklund et al., 2007).  This study suggested that the 
posttraumatic brain may have a transient period for increased regenerative potential, in 
which therapeutic interventions may be able to enhance the endogenous plasticity 
response.  In the current study, which also employed the L-FPI model, we found that GAP-
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43 levels were significantly decreased at PID7 in the ipsilateral hippocampus when 
compared to sham levels, with no significant differences observed in the contralateral 
hippocampus.  When atomoxetine treatment was administered for 7 days post-injury, 
GAP-43 expression returned to sham levels, suggesting atomoxetine treatment may have 
an effect on post-injury regeneration.  The atomoxetine treated animals, like the injured- 
vehicle treated group, did not show any significant differences from sham levels in the 
contralateral hippocampus, suggesting the change in GAP-43 protein expression observed 
in the ipsilateral cortex was related to atomoxetine’s effects on the injured brain.  
The decrease in GAP-43 observed in injured- vehicle treated animals may indicate 
an inhibition of axonal plasticity that occurs following injury or may be a result of cell loss 
in the hippocampus.  Previous studies have found that GAP-43 levels are increased at 24 h 
and 48 h following mild or moderate TBI, but that this response may be limited 
(Thompson et al., 2006).  Successful neurite outgrowth resulting in functional regeneration 
likely requires a delicate balance between growth promoting and growth-inhibiting cues.  
Although increased GAP-43 expression can not be termed successful regeneration alone, it 
has been postulated to correlate with behavioral recovery following TBI (Hulsebosch et al., 
1998).  Overexpression of GAP-43 has also been shown to increase spinal cord 
regeneration in vivo (Bomze et al., 2001) and play an important role in hippocampal 
synaptic remodeling following denervation (Masliah et al., 1991).  Furthermore, previous 
studies using L-FPI have found that the decrease in GAP-43 expression following injury at 
1 week post-injury can return to sham values with drug treatments initiated during the 
early phase of injury (Marklund et al., 2007).  Although it is unknown whether the increase 
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in GAP-43 following atomoxetine treatment represents successful regeneration based 
solely on this study, taken together with our previous behavioral studies that found 
atomoxetine treatment for seven days following injury leads to long-term cognitive 
enhancement, it appears the increased levels of GAP-43 may contribute to the cognitive 
enhancement observed in previous experiments, although this is merely correlative.  The 
exact mechanism by which atomoxetine influenced GAP-43 expression remains unknown, 
but may involve changes in neurotrophins elicited by extracellular catecholamines and 
their downstream effects on signal transduction. 
Atomoxetine treatment also led to bilateral increases in the neurotrophin BDNF.  
BDNF is an activity-dependant neurotrophic factor, with receptors densely distributed 
throughout the CNS (Altar et al., 1994).  BDNF has been implicated in hippocampal 
learning and memory, and enhanced expression of BDNF has been correlated with 
improved cognition (Bramham and Messaoudi, 2005, Ando et al., 2002).  Following TBI, 
increases in the levels of BDNF have been reported at different time points (Hicks et al., 
1997; Chen et al., 2005).  In general, changes in BDNF expression have been explained by 
alterations in BDNF production, degradation, or neuronal transport.  In this study 
performed at day 7 post-injury, BDNF expression in injured-vehicle treated animals was 
not significantly different from sham animals in the ipsilateral or contralateral 
hippocampus.  The injured-atomoxetine treated group displayed small, yet significant 
increases in the levels of BDNF in both the ipsilateral and contralateral hippocampus 
compared to both sham and injured-vehicle treated groups.  This is suggestive of an 
enhanced structural recovery correlated with improved behavioral outcome following 
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atomoxetine treatment; however, the exact mechanism remains unknown.  One conclusion 
may be that increased BDNF in the hippocampus, created a more favorable environment 
for regeneration, increased survival and maturation of newborn granule cells, and/or 
enhanced synaptic plasticity, which as a consequence enhanced cognition.  Functionally, 
BDNF plays a role in facilitating synaptic transmission and is associated with LTP 
(Patterson et al., 1996).  This increased plasticity may allow for increased cognitive 
flexibility, which enables animals to perform better in cognitive tasks (for a review, see 
Cui, 2006).  Moreover, in vitro studies have shown that neurons stimulated with BDNF 
have an enhanced ability to counteract the effects of myelin-associated inhibitors through a 
mechanism involving the action of protein kinase A (Cai et al., 1999; Gao et al., 2003).  
Therefore, increased BDNF levels have been associated with increased levels of GAP-43 
and may have contributed to the increase in GAP-43 observed in the current study.  In 
addition, several studies have found that increased BDNF following injury is correlated 
with improved behavioral outcome.  For example, environmental enrichment and delayed 
exercise have both been shown to increase hippocampal BDNF levels and improve 
cognition following injury (Chen et al., 2005; Chytrova et al., 2008).  The increase in 
BDNF expression in the contralateral hippocampus following atomoxetine treatment, 
suggests atomoxetine may have an effect globally on BDNF levels, which may represent a 
compensatory recovery mechanism stimulated by atomoxetine in areas remote from the 
injury.  Previous studies have found elevated BDNF levels in the contralateral cortex at 
72h after injury in rats (Hicks et al., 1997), however, we found no differences in BDNF 
expression from sham in the injured- vehicle treated animals.  Therefore, it may be that 
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atomoxetine treatment is necessary for such compensatory mechanisms.  Alternatively, the 
bilateral expression of BDNF may suggest atomoxetine affects BDNF expression through 
mechanisms that are unrelated to TBI.  No previous studies have investigated 
atomoxetine’s effects on BDNF in naïve animals.      
   BDNF is partially localized to NE nerve fibers and terminals and is synthesized and 
transported by LC neurons (Fawcett et al., 1998).  Overexpresion of BDNF in NE neurons 
results in increased activation of trkB and long-lasting changes in neuronal survival and 
organization.  The increase in BDNF expression following atomoxetine treatment in the 
current study is also in line with several studies that suggest NE-enhancing drugs can 
increase the levels of neurotrophins in the adult brain (Aloyz et al., 1999; Calabrese et al., 
2007).  Several studies have found that antidepressant treatment induces up-regulation of 
BDNF (Nibuya et al., 1995), and increases neurogenesis in the adult rat hippocampus 
(Malberg et al., 2000), although it is unknown which neurotransmitter system is most 
responsible for these effects.  These studies also suggest that chronic treatment, rather than 
a single dose, is necessary for significantly increased BDNF expression (Calabrese et al., 
2007), which is inline with our behavioral results that found only a modest non-significant 
change in cognition following a single treatment.  Therefore, increased neurotrophin 
expression may represent adaptive structural changes after repeated atomoxetine 
treatments.  Moreover, alterations in neuronal activity can up-regulate BDNF mRNA and 
induce prolongation of its stability (Ghosh et al., 1994; Fukuchi et al., 2005), thus the 
downstream effects of atomoxetine on other neurotransmitters and an overall stimulation 
of neuronal activity may also be responsible for the increase in BDNF.  Further evidence 
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comes from the studies that show neural activity regulates the induction and release of 
BDNF (Poo, 2001; Lessmann et al., 2003), and NE modulates BDNF expression in 
neurons and astrocytes (Juric et al., 2006).  Therefore, another potential mechanism for 
atomoxetine’s effects on BDNF expression may involve activation of astrocytes. 
The present study at 7 days following injury found no differences in the levels of 
synaptophysin between any groups.  Changes in synaptophysin immunoreactivity have 
been used previously to characterize both synaptic loss and formation of new synapses.  
Synaptophysin expression has been shown to increase in parallel with the formation of 
synapses during development and reorganization (Calhoun et al., 1996).  Previous studies 
found synaptophysin is increased beginning at 10 days post-injury and lasts as long as 60 
days following experimental brain injury (Scheff et al., 2005; Thompson et al., 2006).  In 
the current study, it may be possible that atomoxetine affected synaptophysin but that this 
effect was masked by the loss of synapses.  However, this is unlikely because we found no 
significant differences between injured-vehicle treated and sham groups.  One caveat is 
that only one time point was analyzed.  Several studies have previously characterized the 
time course for the expression of synaptophysin following injury and suggested that 
increases in synaptophysin follow increases in the expression of GAP-43.  Therefore, a 
later time point may be more appropriate to investigate the effects of atomoxetine on the 
expression of synaptophysin.     
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Figure 11 Ipsilateral GAP-43 Western Blot (A-D).  A. Western blot for GAP-43 protein 
from the hippocampus of injured-vehicle treated, sham, and injured-atomoxetine treated 
groups B. The negative control, in which primary antibody was omitted, showed no 
staining, demonstrating the primary antibody is specific for GAP-43.  C.  A one-way 
ANOVA found no significant differences in the expression of beta-Actin between the 
groups (F (2, 12) = 2.224 P =.151), indicating equal loading of protein in each lane.  D.  
The effect of atomoxetine on GAP-43 expression following injury.  The graph shows the 
quantified optical density measurements from the Western Blot.  There was a significant 
decrease from sham levels in the injured-vehicle treated groups (P=.034).  Injured animals 
treated with atomoxetine returned GAP-43 expression to sham levels (P=.204). (* is P<.05, 
** is P<.01, compared to Injured-Vehicle Treated Group)    
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Figure 12 Contralateral GAP-43 Western Blot.  The western blot for GAP-43 (46 kDA) 
expression in the contralateral hippocampus is shown.  All three groups (n=4) were run on 
the same gel.  No significant differences were found between the groups (P=.278). 
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Figure 13 Ipsilateral Synaptophysin Western Blot.  The western blot for Synaptophysin 
(38 kDA) expression in the ipsilateral hippocampus is shown.  All three groups (n=5) were 
run on the same gel.  No significant differences were found between the groups (P= .501).  
The actin blot also revealed no significant differences among groups. 
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Figure 14 The expression of BDNF in the Ipsilateral and Contralaterl Hippocampus.  
a. The western blot for BDNF (14 kDA) expression in the ipsilateral hippocampus of 
injured-vehicle, sham-injured, and injured-atomoxetine treated animals.  A one-way 
ANOVA found no significant differences between the groups (F (2,12)=3.441, p=.066); 
however, pare-wise comparisons using the Least Significant Differences (LSD) test found 
a significant increase in the expression of BDNF in the hippocampus of injured- 
atomoxetine treated animals over sham-injured animals (P= .027), suggesting atomoxetine 
treatment may influence neurotrophins when given chronically after injury. 
b. The western blot for BDNF expression in the contralateral hippocampus of injured-
vehicle, sham-injured, and injured-atomoxetine treated animals. Analysis of the 
contralateral hippocampus (Fig. 13b) found a significant effect on group (F (2, 10) =5.455, 
P=.025).  Post-hoc comparisons using the LSD test found there was a significant increase 
in BDNF expression in atomoxetine treated animals over sham-injured animals (P=.020).    
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Experiment 6: Immunohistochemistry for GAP-43 in the Hippocampus 
Rationale:  Western Blot analysis found a significant change in the expression of 
GAP-43 protein levels at PID 7.  Therefore, we decided to employ immunohistochemistry 
techniques to observe specific changes in GAP-43 expression in different regions of the 
hippocampus.    
Design: Animals were randomly separated into one of three groups: injured + 
saline treatment (n=5), injured + 1 mg/kg atomoxetine treatment (n=5), and sham-injured 
(n=5).  Animals were injured and sham-injured as described previously. Beginning 24h 
after injury, animals received either saline or 1 mg/kg atomoxetine depending on group 
assignment.  Treatment continued for 7 days.  On PID 7, animals were anesthetized with 
100 mg/kg pentobarbital and fixed via cardiac perfusion with saline followed by 4% 
paraformaldyhide, in .1M phosphate buffer, pH 7.2.  Sham animals were likewise 
sacrificed at the same time points.  Following perfusion, brains were removed and placed 
in paraformaldyhide for 1-3 days, and then placed in Millonig’s Phosphate Buffer Solution 
and stored at 4°C.  Several naïve animals were used as controls.      
Immunohistochemistry Procedure 
 The brains were sliced on a vibratome into 40µm thick sections, and sections 
containing rostral (-3.6 mm from bregma) to caudal (-4.2mm from bregma) hippoampal 
regions were used for immunohistochemistry.  The immunohistochemistry procedure was 
performed on 5 sections from each brain for all three groups.  The slices were washed in 
phosphate buffer saline (PBS) three times for five minutes, and then incubated in 5% 
H2O2for 30 minutes to quench endogenous peroxidases.  After three additional 5 minute 
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washes in PBS, the slices were incubated in .1M PBS with Triton X/ 10%normal horse 
serum.  Sections were then incubated overnight at 4°C in a 1:2000 concentration of a 
mouse anti-GAP-43 (7B10, Invitrogen).  On day two, the sections were washed 3 times for 
10 minutes, and then incubated at room temperature for 1h in biotinylated secondary 
antibody (1:200, ImmunoPure Ultra-Sensitive ABC Mouse IgG Staining Kit, Pierce).  
After additional washes, sections were incubated for 1h at room temperature with ABC 
reagent (Pierce) and developed with diaminobenzadine (DAB substrate kit, Zymed).  
Sections were mounted onto gelatin-coated slides, dehydrated and cover-slipped.  
Application of control serum instead of primary antibody on selected sections of rat tissue 
provided a negative control.    
Densitometric Analysis 
Slides were coded and the data was collected by an observer unaware of treatment 
group.  Each group contained 5 animals, and 5 slices were analyzed from each animal.  
Images were captured using a Nikon Optiphot-2 microscope equipped with a MRI-103 
driver for a MAC 2000 motorized stage and a MTI 3CCD video camera interfaced with the 
MicroBrightfield Neurolucida software.  Images were analyzed using IPLab 3.7 (BD 
Biosciences). The igages were first converted to grey scale before analysis.  The borders of 
each region were traced manually and the pixels per area were then automatically 
calculated using image analysis software after defining a threshold for the background. 
Results 
The IR for GAP-43 was observed in the stratum oriens, stratum radiatum, stratum 
lacunosum moleculare, and inner molecular layer of the denate gyrus.  GAP-43 
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immunoreactivity was characterized by a laminar immunostaining pattern.  There was no 
visible staining in the negative controls (data not shown).  Compared to uninjured-sham 
animals (Figure 15A) increases in IR for GAP-43 were observed at 7 days post-injury 
within the IML of the dentate gyrus and SLM of CA1 of the hippocampus.  Densitometric 
analyses using a one-way ANOVA found a significant effect of group in the IML of the 
dentate gyrus (Fig 15B, F (2, 12) =15.280 P=.001).  Pair-wise comparisons using Tukey’s 
HSD test revealed there was a significant increase in GAP-43 expression from sham levels 
in both injured-vehicle treated (P<.05) and injured-atomoxetine treated animals in the IML 
(P<.001).  Although GAP-43 IR was not significantly higher in the injured-atomoxetine-
treated group compared to injured-vehicle treated  in this region, there was a trend towards 
increased GAP-43 in the injured-atomoxetine-treated group that reached significance over 
the injured-vehicle treated group when a less stringent post-hoc test, the LSD test, was 
used (P=.030).  A one-way ANOVA also found a significant effect on GAP-43 IR in the 
SLM in CA1 of the hippocampus (F (2, 12) =5.628 P=.019).  Tukey’s HSD found a 
significant increase in the expression of GAP-43 in the SLM region relative to sham levels 
in the atomoxetine treated group (P<.05).  There were no significant differences found 
between sham and injured-vehicle groups or between the two injured groups in this region 
of the hippocampus.  All other regions of the hippocampus analyzed revealed no 
significant differences between groups (data not shown).   
 The contralateral hippocampus was also analyzed for differences in GAP-43 IR 
(Figure 16).  There were no significant differences found between the uninjured-sham 
group and the injured-vehicle treated group in any of the regions analyzed in the CL 
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hippocampus.  However, there was a significant increase in GAP-43 IR found between the 
injured-atomoxetine treated group in the IML of the hippocampus compared to both Sham 
(P<.001) and injured-vehicle treated groups (P<.001), suggesting atomoxetine treatment 
affected GAP-43 expression in both hemispheres of the IML.  In the SLM of CA1 in the 
hippocampus, GAP-43 IR was increased modestly, yet significantly, in the injured-
atomoxetine treated group over the sham (P=.03), although no differences were observed 
in the SLM between atomoxetine-treated animals and sham animals, or between sham 
animals and injury-vehicle treated animals.    
Discussion 
 In the present study, we investigated the effects of chronic atomoxetine treatment 
on injury-induced changes in GAP-43 using immunohistochemistry and image analysis.  
The results indicated that (1) GAP-43 expression was increased in the IML of the dentate 
gyrus of the hippocampus in injured-vehicle treated animals compared to sham-injured 
animals, (2) atomoxetine treatment for 7 days following L-FPI increased GAP-43 
expression in the ipsilateral and contralateral IML and SLM region of CA1 when 
compared to shams and (3) atomoxetine treatment following injury increased GAP-43 
expression relative to injured-vehicle treated in the IML of the contralateral hippocampus.   
 Numerous studies have demonstrated that GAP-43 plays an important role in 
axonal outgrowth, regeneration, and neuroplasticity (for review, see Emery et al., 2003). 
Overexpression of GAP-43 following injury has been correlated with improved behavioral 
recovery (Holesbosch et al., 1998; Marklund et al., 2007).  Previous studies using 
immunohistochemistry techniques found that GAP-43 expression is increased early after 
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injury but returns to sham levels by PID 7, indicating a limited regenerative response 
(Emery et al., 2000; Marklund et al., 2007).  In the current study using 
immunohistochemistry performed on PID 7, we found that GAP-43 levels were 
significantly increased in the IML of the dentate gyrus of the ipsilateral hippocampus of 
injured-vehicle treated animals relative to sham.  No significant differences were found 
between injured-vehicle treated animals and sham animals in any of the other regions of 
the hippocampus (ipsilateral and contralateral) that were analyzed.  These results using 
immunohistochemistry differ from those obtained in the previous experiment using 
western blot analysis, in which we found a decrease in GAP-43 in the ipsilateral 
hippocampus that was restored to sham levels by daily administration of atomoxetine 
treatment for 7 days following injury.  The current study using immunohistochemistry also 
found that atomoxetine treatment following injury increased GAP-43 expression compared 
to Sham, specifically in the dentate gyrus and SLM region of CA1.  In contrast to the 
previous study, we found no decreases in injured-vehicle treated animals from sham levels 
in GAP-43 expression in any of the regions analyzed and even found an increase over 
sham levels in the IML.  Therefore, the immunohistrochemistry results do not directly 
confirm the results obtained from western blot analysis.  The different results from these 
two studies may partially be explained by the experimental differences in the techniques 
used.  For example, western blot analysis uses tissue from the entire hippocampus (dorsal 
and ventral), whereas the results from the immunohistochemistry reflect specific regions 
from only dorsal sections of hippocampus.  Some of the subtle changes that are expressed 
in specific regions of the hippocampus following immunohistrochemistry may be missed 
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using western blot.  The differences also may be explained on the basis of injury variability 
between animals.  
The increased expression of GAP-43 observed in the IML following injury likely 
represents sprouting of associational/commissural fibers and synaptic reorganization 
occurring following injury. The mossy cells of the hilar region of the hippocampus 
constitute the majority of the fibers innervating the inner third of the dentate gyrus.  There 
was a trend towards increased GAP-43 expression in the IML of atomoxetine treated 
animals following injury compared to injured-vehicle treated groups. Functionally, it is 
unknown what an increase in GAP-43 in this region may represent.  Several studies have 
found aberrant sprouting of mossy fibers in this region is associated with maladaptive 
plasticity (Longo et al., 2005).  Our behavioral results indicated that atomoxetine improved 
cognitive function following injury, suggesting the small increase in GAP-43 in this region 
may not be representative of maladaptive plasticity.  Although it is unknown what the 
small increase in GAP-43 following atomoxetine treatment represents functionally, several 
studies have shown drugs that affect the NE system may influence GAP-43 in this region.  
For example, imipramine, a NE reuptake inhibitor that also influences other monoamines, 
increases GAP-43 specifically in the IML and SLM of the hippocampus of naïve adult 
male Wistar rats (Sairanen et al., 2007).  Desiparmine, a NE reuptake inhibitor, specifically 
increased GAP-43 expression in the dentate gyrus.  Furthermore, in vitro studies in 
hippocampal cultured cells have found administration of NE leads to increased GAP-43 
expression, concurrent with increases in neurite outgrowth-promoting genes (Laifenfeld et 
al., 2002).  Although, the mechanism is unknown, it may involve the role of NE in LTP in 
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the hippocampus and may be related to activation of cAMP AND PKA.  In the 
hippocampal formation, noradrenergic innervation is particularly dense in areas receiving 
mossy fiber inputs, including the hilus of the dentate gyrus and stratum lucidum of the 
CA3 (e.g., Moudy et al., 1993).  Interestingly, GAP-43 expression was increased over 
sham animals in the iml of both the ipsilateral and contralateral hippocampus, suggesting 
the changes in GAP-43 following atomoxetine treatment may not be directly related to TBI 
pathology.  
 The other region of the hippocampus that displayed a change in GAP-43 was the 
SLM of CA1.  The SLM region of CA1 receives lateral perforant pathway input, as well as 
Shaffer collaterals from CA3.  GAP-43 expression was increased relative to sham animals 
in this region following atomoxetine treatment for 7 days post-injury in both the ipsilateral 
and contralateral hippocampus.  Therefore, atomoxetine treatment may have an influence 
on synaptic plasticity and reorganization occurring in this region.  The influence of 
dopamine may be particularly important regarding synaptic plasticity in this region.  D1 
receptor activation can mimic LTP-inducing electrical stimulation to produce GAP-43 up-
regulation in CA1 (Williams et al., 2006). The occurrence of late phase-LTP in CA3-CA1 
and subsequent up-regulation of GAP-43 in hippocampus is simultaneously blocked by 
SCH23390, a selective DA1R antagonist (Chirwa et al., 2004). 
 
   
.   
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Figure 15 GAP-43 Immunohistochemistry in the Ipsilateral Hippocampus.  A.  
Representative photomicrographs of GAP-43 staining in the ipsilateral hippocampus of 
Sham, Injured-Vehicle treated, and Injured- Atomoxetine Treated Animals (10X) at 7 days 
post-injury.  B.  Densitometric analysis of GAP-43 immunoreactivity within individual 
hippocampal regions revealed statistically significant increases.  Pair-wise comparisons 
using Tukey’s HSD test revealed there was a significant increase in GAP-43 expression 
from sham levels in both injured-vehicle treated (P<.05) and injured-atomoxetine treated 
animals (P<.001) in the IML of the dentate gyrus.  Although GAP-43 IR was not 
significantly higher in the atomoxetine treated group compared to injured-vehicle treated, 
there was a trend towards increased GAP-43 in the atomoxetine-treated group that reached 
significance over the injured-vehicle treated group when a less stringent post-hoc test, the 
LSD test, was used (P=.030).  A one-way ANOVA also found a significant effect on GAP-
43 IR in the SLM of the hippocampus (F (2, 12) =5.628 P=.019).  Tukey’s HSD found a 
significant increase in the expression of GAP-43 in the SLM of CA1 from sham levels in 
the atomoxetine treated group (P<.05).    
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Figure 16 GAP-43 Densitometric analysis in the Contralateral Hippocampus. No 
significant differences found between the uninjured-sham group and the injured-vehicle 
treated group in any of the regions analyzed in the CL hippocampus.  A. There was a 
significant increase in GAP-43 IR found between the injured-atomoxetine treated group in 
the IML of the hippocampus compared to both Sham (P<.001) and injured-vehicle treated 
groups (P<.001).  B.  In the SLM of the hippocampus, GAP-43 IR was increased modestly, 
yet significantly, in the atomoxetine-treated group over the injury-vehicle treated group 
(P=.03).  
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CHAPTER 4 GENERAL DISCUSSION 
 
Summary of Results 
The studies presented here investigated whether the pharmacological enhancement 
of catecholamines with atomoxetine treatment following TBI affects cognitive outcome 
and the potential mechanism for any beneficial effect.  Several different behavioral 
paradigms were used to investigate important questions of treatment dose, therapeutic 
window, and duration of treatment.  In addition, several markers were used to investigate 
how atomoxetine may affect post-injury plasticity and reorganization.  1.)  Low doses of 
atomoxetine are effective an attenuating cognitive deficits caused by experimental TBI 
when daily treatment was initiated 24h after injury.  2.) When chronic treatment was 
initiated at a delayed time point of 10 days, atomoxetine did not provide the same 
beneficial effects, suggesting atomoxetine’s mechanism for enhanced cognition may be 
related to post-injury mechanisms that are occurring within the first week post-injury. 3.)  
We further demonstrated that daily atomoxetine treatment during the first seven days post-
injury can provide an enhancement of cognitive deficits even after its termination, but was 
not as effective when a single dose was given, suggesting chronic treatment is necessary 
for behavioral enhancement.  4.)  Our final studies found that daily atomoxetine treatment 
for 7 days following injury increases GAP-43 protein expression and modestly increases 
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BDNF protein expression in the hippocampus.  The western blot results found atomoxetine 
treatment can increase ipsilateral GAP-43 expression to sham levels, in comparison to a 
decrease relative to sham observed in injured-vehicle treated animals.  Furthermore, we 
found a bilateral effect of atomoxetine treatment on BDNF levels in the hippocampus, 
suggesting atomoxetine may influence plasticity by increasing neurotrophins.  
Immunohistochemistry analysis found that atomoxetine treatment increased GAP-43 in 
both the IML of the dentate gyrus and SLM of CA1 in the ipsilateral and contralateral 
hippocampus.  Collectively, these observations support the hypothesis that catecholamines 
are active participants in the recovery process following injury, and that pharmacological 
enhancement of these systems may be able to influence the structural and functional 
reorganization following injury. 
 
Clinical Implications  
In terms of post-injury therapeutic treatments, perhaps one of the more important 
observations from this research is that daily atomoxetine treatment during the early phases 
of injury enhances cognition.  Several experimental studies have found similar results 
using pharmacological agents that affect the monoamines, including stimulants, 
antidepressants, dopamine agonists, and MAO-inhibitors (Kline et al., 2000; Kline et al., 
2002; Zhu et al., 2000).  A percent improvement score was calculated for several 
treatments to better understand overall effectiveness and allow for a comparison between 
atomoxetine and previous experimental pharmacological treatments.  The score is a ratio of 
treatment improvement over total deficit (Figure 17, Whiting and Hamm, 2006).  Although 
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this score is an approximation that does not take into account differences in injury models 
and experimental parameters, it does allow for a basic comparison between the effects of 
pharmacological treatments on cognitive enhancement after injury.  Chronic atomoxetine 
(1 mg/kg) treatment produced a percent improvement score of 65%, similar to that 
observed in experimental studies with methylphenidate (53%), bromocriptine (56%), and 
L-Deprenyl (66%), confirming that catecholaminergic agonism is an effective target for 
therapeutic treatments following injury.   
One of the biggest challenges in TBI research is the translation of experimental 
research to the clinical setting.  Clearly there are differences between humans and animals 
that may contribute to failed clinical trials; however, there are several factors that can be 
addressed in experimental studies.  Preclinical studies need to address the important issues 
of treatment dose, timing of treatment initiation and duration.  The behavioral studies in 
this study were especially important because they incorporated a complete dose-response 
analysis and investigated the therapeutic potential of atomoxetine over a relatively long 
post-injury time window.  In addition, this study addressed the effects of terminating 
pharmacological treatment before behavioral testing to examine atomoxetine’s effects on 
long-term outcome.  The behavioral data revealed that low doses of atomoxetine are 
effective when initiated early after injury, but not as effective when delayed for several 
days (10 days).  Although few experimental studies have addressed this issue, these results 
are similar to previous studies with pharmacological agents such as BIBN-99 and MDL 
26479 that found enhanced cognitive recovery when initiated at 24 h becomes ineffective 
when initiated at 10 days post-injury (O’Dell and Hamm, 1995; Pike and Hamm, 1995).  
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Atomoxetine was also able to enhance cognition after cessation of treatment, suggesting 
the early phase following injury is the critical time point for effective therapeutic 
interventions with this drug.  The results also suggest daily atomoxetine treatment may 
have long-term effects on functional outcome if initiated during the time period of post-
injury-induced plasticity and continued chronically.   Similar results were found using L-
Deprenyl following TBI, in which improved cognitive outcome was correlated with 
changes in dopamine beta-hydroxylase IR and acetylcholinesterase histochemistry in the 
injured hippocampus (Zhu et al., 2000).  The authors of this study concluded that 
catecholaminergic enhancement facilitated cognitive recovery and was correlated with 
enhanced synaptic plasticity in the hippocampus.  The results of the current studies suggest 
atomoxetine may have similar effects on post-injury plasticity, although this should be 
confirmed in other experimental injury models and different laboratories. Taken together, 
the results provide valuable information that may be used as a basis for clinical trials with 
atomoxetine.  
 Atomoxetine has several advantages over some of the current treatments being 
used following injury in that atomoxetine is a non-stimulant NET inhibitor and therefore 
has little addictive potential.  Further, it is effective with once daily dosing and has been 
shown to effectively alleviate symptoms of ADHD, as well as co-morbid symptoms of 
depression and anxiety, which are all common complaints following injury (Pataki et al., 
2004; Ripley et al., 2006).  There are also studies that suggest atomoxetine may enhance 
memory in both animals and humans (Foster et al., 2006; Tzavara et al., 2006).  Although 
attention, memory, information processing and emotional disorders all depend on specific 
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neural networks and specific cellular and molecular events, there is significant evidence 
that these circuits overlap and are less differentiated.  For example, arousal and 
information processing speed underlie virtually every aspect of cognitive performance. 
Depression, likewise, is associated with cognitive dysfunction at many levels of analysis.  
Drugs with potent noradrenergic effects have been suggested to be overall cognitive 
enhancers due to the effects of NE on arousal and its faciliatory role in LTP.  Therefore, 
atomoxetine may have similar effects in the TBI population.  
In summary, atomoxetine is a FDA approved drug with relatively few side effects 
in the dose range of .3-3 mg/kg.  At these doses, the drug did not induce any significant 
changes in animal body weight or produce observable side effects.  Atomoxetine did 
produce significant improvements in the MWM by i.p. injection, which is an accepted 
method for delivery in the clinical setting (Magyar et al., 1995).  The current studies 
demonstrated that low doses of atomoxetine improved cognitive performance when 
initiated early and given daily for 7 days following L-FPI.  
 
Potential Mechanisms for Atomoxetine’s Effects 
The present studies further examined the possibility that the therapeutic effect of 
atomoxetine was related to catecholaminergic effects on neural plasticity and 
reorganization following TBI, similar to that observed by Zhu et al. (2000).  Beneficial 
effects of pharmacological agents on brain plasticity and reorganization have previously 
been demonstrated in TBI.  Drugs that affect the catecholamines, such as amphetamine, 
methylphenidate, and bromocriptine have all been shown to affect cortical motor plasticity 
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through mechanisms that likely involve LTP (Schwenkreis et al., 1999).  Numerous studies 
following experimental TBI have also demonstrated that pharmacological enhancement 
with monoamines leads to improvements in cognitive function that are associated with 
structural reorganization (for a review, see Whiting and Hamm, 2006; Tenovuo, 2007).  
Furthermore, perturbations of NE activity play a central role in the development of 
diaschisis and hinder neural recovery.  Although few experimental studies have been done 
with atomoxetine, several studies have found that drugs that affect extracellular levels of 
monoamines can affect synaptic plasticity and/or neurogenesis.  For example, depression 
and chronic stress have been associated with impairments of structural plasticity (Fuchs et 
al., 2004), and there are multiple theories regarding antidepressant treatment effects on cell 
survival and function and the reversal of stress-induced effects (Duman et al., 2000; 
Morishita and Aoki, 2002).  In addition, the actions of NE and DA alter intracellular 
signaling pathways and neurotrophic factors, thus changing the electrophysiological and 
morphological properties of neurons (Stewart and Reid, 2000).  NE has been associated 
with changes in BDNF expression and NGF, which may positively influence the post-
injury environment (Fawcett et al., 1998; Ivy et al., 2003).  NE may also effect cell 
proliferation and/or differentiation of new neurons or non-neuronal cells (Kulkarni et al., 
2002).  The ability of NE to influence such processes is in line with the latter’s 
documented role in neuroplasticity as expressed in the modulation and induction of LTP 
and in memory formation.  Finally, the current study is important in that it confirms 
previous work that suggested pharmacological enhancement of GAP-43 during periods of 
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post-injury plasticity is correlated with improved behavioral (cognitive and motor) 
outcome (Ramic et al., 2006; Chytrova et al., 2007; Marklund et al., 2007).   
The exact cellular mechanisms underlying atomoxetine-induced cognitive 
improvements and changes in GAP-43 and BDNF expression after TBI remain unclear.  
One mechanism by which atomoxetine resulted in the observed effects likely involves the 
role of NE is regulating neuronal activity.  Increased NE facilitates positive signaling and 
trophic influences through the recruitment of adrenergic receptors, activation of ion 
channels and the second and third messenger cascades downstream of these receptors (e.g., 
cAMP, protein kinase A, CREB). The effects observed in these experiments following 
atomoxetine treatment may be a direct effect of NE agonism at the synapse.  Experimental 
TBI has been associated with depressed levels of cAMP and PKA for several days 
following injury (Atkins et al., 2007).  NE and DA activate G proteins that in turn alter 
membrane excitability and act through second messengers within the neurons.  Protein 
kinases are important second messengers that phosphorylate proteins and alter the 
sensitivity of receptors, the responsiveness of ion channels and the regulation of gene 
expression.  These cascades drive the release of other neurotransmitters and upregulate 
endogenous neurotrophin systems.  For example, the basolateral cholinergic system 
receives noradrenergic innervation, and drugs that increase norepinephrine, including 
atomoxetine, also increase the release of acetylcholine, which is affected following TBI 
(Dalley et al., 2004; Tzavara et al., 2005).  In light of the role of acetylcholine in memory 
functions, any drug that increases levels of acetylcholine would in theory enhance 
cognition.  Indeed, CDP-choline significantly increases extracellular levels of 
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acetylcholine, and significantly improves performance in the MWM following 
experimental TBI (Dixon et al., 1997).  NE can also regulate both glutamate and GABA 
transmission and, therefore, balance excitatory/inhibitory homeostasis in specific circuits 
and contribute to the tuning of memory processes (Tan et al., 2006; Zsiros et al., 2008).  
NE, acting through beta-adrenergic receptors, affects both PKA and cAMP.  PKA and 
cAMP signaling have been shown previously to regulate the capacity of dorsal root 
ganglion and retinal ganglion cell neurons to grow axons in both permissive and inhibitory 
cultures (Cai et al., 2001; Shearer et al., 2003).  Furthermore, PKA inhibitors decreased the 
ability for growth cone formation following in vitro axotomy, and pharmacological 
treatments that increase cAMP and PKA promote growth cone regeneration in adult retinal 
ganglion cell axons in culture (Chierzi et al., 2005).  NE application to cultured 
hippocampal cells has been shown to increase GAP-43, as well as growth promoting 
genes, suggesting there may be a similar effect in vivo, following an increase in 
extracellular NE.  Dopamine has similar effects on cAMP via activation of D1 like 
receptors.  Administration of D1/D5 receptor agonists increases cAMP levels and activates 
PKA (Bach, 1999).  PKA activation has been linked with memory functions that depend 
on the hippocampus, and has been shown to reverse long-term memory deficits (Kandel, 
2001).  However, other studies have found that long-term elevation of intracellular cAMP 
levels in rat primary cortical cultures results in a persistent downregulation of GAP-43 
(Krueger and Narin, 2007).  Therefore, it appears that increasing cAMP and PKA may lead 
to different effects depending on the circuits and brain regions they are located.   
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NE may also modulate BDNF expression in both neurons and astrocytes (Juric et 
al., 2006).  BDNF is thought to mediate activity-dependent synaptic plasticity in the 
mature nervous system, and increases in neural activity lead to increases in BDNF (Poo, 
2001; Lessmann et al., 2003).  A positive cooperativity between increased extracellular 
levels of NE and enhanced BDNF may interact to influence plasticity and regeneration in 
the injured brain.  BDNF shows a high-affinity for tropomyosin-related kinase (TrK) B. 
Several studies have implicated BDNF-TrKB signaling in gene regulatory events that 
contribute to neuronal survival, synaptic plasticity and learning and memory (Cui, 2006).  
In vitro studies have found BDNF application to cultured hippocampal neurons elicits a 
rapid potentiation of excitatory synaptic transmission and facilitates LTP (Lessmann et al., 
1994; Figurov et al., 1996).  These rapid changes can lead to structural changes, such as 
axonal branching and dendritic growth after exposure to BDNF for longer periods of time 
(Cohen-Cory et al., 1995; McAllister and Katz, 1999).  In addition, several in vitro studies 
have demonstrated that neurons primed with BDNF become resistant to the inhibitory 
actions of MAG (Myelin Associated Glycoproteins), and thus elevate the capacity of the 
injured brain to overcome the limitations in regeneration (Cai et al., 1999; Gao et al., 2003; 
Spencer and Filbin, 2004).  NE receptors are also located on glial cells, and these receptors 
may indirectly modify the extracellular milieu by increasing neurotrophins (Aoki et al., 
1987; Tsacopoulos et al., 1996).     
BDNF has previously been associated with postinjury recovery periods, and 
changes in GAP-43 have been correlated to changes in BDNF (Chytrova et al., 2008). 
Therefore, the small, yet significant, increases in BDNF observed following atomoxetine 
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treatment may contribute to the changes in GAP-43 that are observed, although this theory 
requires further studies.  The changes in hippocampal GAP-43 protein expression in the 
current studies were observed in areas of the hippocampus that contain dense NE 
projections, suggesting local increases in extracellular NE may influence regeneration, 
possibly through a mechanism involving BDNF.  BDNF may positively influence the 
cellular environment and thus affect synaptic reorganization following injury.  Although 
we did not observe any changes in BDNF in our injured-vehicle treated animals in this 
experiment, recovery following TBI may require increased BDNF for restoration of 
function.  In addition, it can not be ruled out that atomoxetine’s effects on cognition were 
not related to changes in brain regions other than the hippocampus.  Therefore, future 
studies will investigate changes in these markers in other brain regions.   
Alternatively, atomoxetine may act through other mechanisms that are involved in 
TBI pathology.  NE is released at the synapse as well as extrasynaptically.  Extrasynaptic 
NE has been hypothesized to play a role apart from its role as a neurotransmitter.  Immune 
cells express various neurotransmitter receptors that are sensitive to monoamines, and the 
production of cytokines and other immune/inflammatory mediators (such as free radicals) 
are modulated by activation of these receptors (Elenkov et al., 2000). The interactions of 
the catecholamines and the immune system, including cytokines may be another 
mechanism by which atomoxetine acts following injury.  Although not addressed in this 
dissertation, neurotransmitter receptors found on immune cells are sensitive to 
monoamines, and the production of cytokines (and other immune/inflammatory mediators 
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such as chemokines and free radicals) is modulated by activation of these receptors 
(Elenkov et al., 2000). 
 Neurotransmitters can initiate signal transduction pathways that modulate the 
cytokine production of the cell.  NE alters functions such as cytokine production and 
cellular responses to cytokines, and inflammatory gene expression (Hu et al., 1991).  For 
example, NE blocks the expression of inflammation-induced proteins, including major 
histocompatibility complex class II (Frohman et al., 1988) tumor necrosis factor-α (Hu et 
al., 1991), interleukin-1Β (IL-1B) (Willis and Nisen, 1995), and inducible nitric oxide 
synthase (iNOS) in astrocytes and microglia (Feinstein et al., 2002).  In contrast, NE 
depletion reinforces the increase of iNOS, IL-1B, and cyclooxygenase-2 (Heneka et al., 
2002).  The process of neurodegeneration has been closely linked with a shift to the 
production of pro-inflammatory cytokines (Feuerstein et al., 1998), and the modulation of 
cytokine balance is governed by the amount of catecholamines in the extracellular space 
(Selmeczy et al., 2003).  It appears that NTs that activate cAMP and adenylate cyclase 
(such as NE) also stimulate anti- inflammatory cytokines (Szelenyi and Vizi, 2006).  For 
these reasons, NE has been suggested to act as an endogenous anti-inflammatory agent- 
reducing pro-inflammatory cytokines and encouraging anti-inflammatory properties 
(reviewd by Feinstein et al., 2002).  Therefore, drugs that affect the NE system may 
influence the immune response directly through adrenergic receptors expressed on 
macrophages and other immunological cells.  It has been suggested that impairments to the 
LC-NE system, because of its immunomodulatory role, may enhance inflammatory 
responses to beta-amyloid and contribute to the pathogenesis of Alzheimer’s.  Drugs that 
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increase NE availability may be able to prevent these inflammatory processes (Heneka et 
al., 2002, 2003).  In conclusion, there are a number of burgeoning theories supported by 
the literature for NE’s role in various processes; however, significant research in these 
fields is required to fully determine the specific mechanism for the results observed.  It is 
possible that atomoxetine may affect functional outcome through multiple mechanisms, 
which will require further research in the context of TBI.     
Conclusions 
Atomoxetine offers potential for a therapeutic treatment to enhance cognition 
following TBI.  These studies suggest low doses of daily atomoxetine initiated 24h after 
injury may also be able to influence post-injury structural and functional outcome.  To 
date, there have been no clinical trials investigating the potential of this drug.  Although 
the results presented in this study are convincing, several questions surrounding 
atomoxetine’s mechanism remain to be answered.  Before clinical trials begin, details 
about atomoxetine’s mechanism of action should be fully investigated and the results 
confirmed in other experimental models.  These studies are the first to show that 
atomoxetine improves cognition that is correlated with structural hippocampal changes. 
Changes in GAP-43, BDNF, synaptophysin, and other markers of synaptic plasticity 
should be investigated at several time points and in additional brain regions.  Atomoxetine 
is a well tolerated drug with few side effects and low addictive potential.  Therefore, 
atomoxetine may be effective alone or in combination with other pharmaceutical and 
rehabilitative therapies, which may provide more successful functional outcomes for brain 
injured patients.  
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Figure 17.  Pharmacological Treatments Following TBI.  The percent improvement was 
calculated as a ratio of treatment improvement over total deficit.  Treatment improvement 
was calculated as the difference in water maze performance between injured-vehicle and 
injured- Treated groups.  The total deficit was calculated as the difference in water-maze 
performance between sham and injured-vehicle treated groups.  The percent improvement 
was based on estimates from published graphs.  Higher percentage scores indicate that the 
treatment was more effective at eliminating injury-induced deficits.     
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